1	result	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	injection	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	corticosteroids	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	to	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	patients	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	shoulder pain	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	due to	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	soft tissue disorders	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	guidance	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	therapeutic effectiveness	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
1	adverse effects	Our results indicate that the injection of corticosteroids to patients with shoulder pain due to soft tissue disorders under the USG-guidance may improve therapeutic effectiveness and reduce adverse effects.	Affirmed
2	given	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
2	anesthesia	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
2	condition	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
2	anaesthesia	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
2	clamp	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
2	associated procedure	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
2	painful	For a given anesthesia condition, the Mogen clamp is associated with a less painful procedure than the Gomco.	Affirmed
3	statistical	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	difference	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	found	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	efficacy	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	citalopram	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	risperidone	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	treatment	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	agitation	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	psychotic symptoms	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	patients	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	psychotic nos	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	patients symptoms	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	psychotic	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
3	dementia	No statistical difference was found in the efficacy of citalopram and risperidone for the treatment of either agitation or psychotic symptoms in patients with dementia.	Affirmed
4	findings	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	need	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	to	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	replicated	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	citalopram	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	antidepressants	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	recommended	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	alternative	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	antipsychotics	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	treatment	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	agitation	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	psychotic symptoms	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	associated with	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
4	dementia	These findings need to be replicated before citalopram or other serotonergic antidepressants can be recommended as alternatives to antipsychotics for the treatment of agitation or psychotic symptoms associated with dementia.	Affirmed
5	conclude	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	losartan	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	alone	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	combination	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	hctz	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	well	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	effective treatment	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	elevated	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	systolic	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	diastolic bp	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	obese	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	patients	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
5	hypertension	We conclude that losartan alone or in combination with HCTZ was generally well tolerated and effective in the treatment of elevated systolic and diastolic BP in obese patients with hypertension.	Affirmed
6	real	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	immediate	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	improvement	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	breast feeding	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	mother	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	sustained	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	not	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	appear	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	to	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	be	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	due to	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
6	placebo effect	There is a real, immediate improvement in breastfeeding, detectable by the mother, which is sustained and does not appear to be due to a placebo effect.	Affirmed
7	birth cohort	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	more	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	one	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	four	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	children	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	wheezing	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	childhood	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	adulthood	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	relapsed	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
7	remission	In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission.	Affirmed
8	factor	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	persistence	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	relapse	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	sensitisation	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	housedust mites	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	airway, nos	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	airway	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	female sex	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	smoking	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
8	early age onset	The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset.	Affirmed
9	findings	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	persistently	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	low	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	lung function	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	suggest	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	outcome	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	adult	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	asthma	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
9	early childhood	These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	Affirmed
10	study	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	negative	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	suggestion	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	benefit	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	methylprednisolone acetate	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	in	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	population	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	adults, young	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	acute low back pain	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
10	root	This study was a negative study, though there was a suggestion of benefit of methylprednisolone acetate in a population of young adults with acute radicular low back pain.	Affirmed
11	patients	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	high risk	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	cardiovascular events	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	but	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	diabetes	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	targeting	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	systolic blood pressure	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	mmhg	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	compared	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	lower	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	rate	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	fatal result	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	major	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	death cause	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	high	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	adverse events	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	observed	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	treatment	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
11	group	Among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group.	Affirmed
12	guidance	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
12	accuracy	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
12	joint injection	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
12	allowing	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
12	rapidly	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
12	high	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
12	rheumatologists	US guidance significantly improves the accuracy of joint injection, allowing a trainee to rapidly achieve higher accuracy than more experienced rheumatologists.	Affirmed
13	procedure	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	delayed time	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	cord	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	clamping	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	less	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	use	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	not	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	compromise	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	preterm infant	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	initial	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	postpartum	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	adaptation	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
13	phase	The procedure of a delayed cord clamping time of at least 30 s is safe to use and does not compromise the preterm infant in the initial post-partum adaptation phase.	Affirmed
14	result	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	suggest	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	medical therapy	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	using	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	alpha	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	antagonists	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	calcium channel blockers	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	augment	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	stone	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	expulsion	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	rate	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	compared	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	standard therapy	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	moderately	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	size	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	distal	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
14	ureteral stone	Our results suggest that "medical expulsive therapy," using either alpha-antagonists or calcium channel blockers, augments the stone expulsion rate compared to standard therapy for moderately sized distal ureteral stones.	Affirmed
15	review, systematic	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	aim	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	aims	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	to	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	evaluate	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	benefit	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	side effect	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	xuezhikang	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	coronary heart disease	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	complicated	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
15	dyslipidaemia	This systematic review aims to evaluate the benefit and side effect of Xuezhikang for coronary heart disease (CHD) complicated by dyslipidemia.	Affirmed
16	all	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	clinical trials, randomized	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	xuezhikang	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	treatment	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	chd	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	combined	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	dyslipidaemia	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	considered	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
16	inclusion	All randomized clinical trials (RCTs) with Xuezhikang as a treatment for CHD combined with dyslipidemia were considered for inclusion.	Affirmed
17	data extraction	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
17	analysis	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
17	quality	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
17	assessment	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
17	conduct	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
17	according	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
17	standards	Data extraction and analyses and quality assessment were conducted according to the Cochrane standards.	Affirmed
18	xuezhikang	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	show	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	significant	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	benefit	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	incidence	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	cause of death	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	chd	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	deaths	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	myocardial infarction	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	revascularisation	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	compared	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	placebo	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	based	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
18	conventional treatment	Xuezhikang showed significant benefit on the incidence of all-cause deaths, CHD deaths, myocardial infarction, and revascularization as compared with placebo based on conventional treatment for CHD.	Affirmed
19	lowered	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	total cholesterol	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	triglyceride	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	low density lipoprotein cholesterol	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	compared	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	placebo	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	inositol nicotinate	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	group	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	similar	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
19	statins	It remarkably lowered total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) as compared with the placebo or inositol nicotinate group, which was similar to statins group.	Affirmed
21	xuezhikang	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	show	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	comprehensive	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	lipid	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	effect	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	effective	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	reducing	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	cardiovascular events	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	chd	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	patients	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	complicated	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
21	dyslipidaemia	Xuezhikang showed a comprehensive lipid-regulating effect and was safe and effective in reducing cardiovascular events in CHD patients complicated by dyslipidemia.	Affirmed
22	bimanual examination	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	pelvic	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	bimanual	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	pelvic examination	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	marked	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	limitations	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	evaluate	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	adnexa	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
22	ideal	Bimanual pelvic examination has marked limitations for evaluating adnexa, even with ideal circumstances.	Affirmed
23	patient characteristics	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	obesity	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	uterine	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	size	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	abdominal scars	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	limit	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	accurate	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	palpation	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
23	adnexa	Patient characteristics such as obesity, uterine size, and abdominal scars limit the accurate palpation of the adnexa.	Affirmed
24	nitrofurantoin	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
24	transport, nos	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
24	milk, human	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
24	transport	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
24	concentrations	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
24	milk	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
24	serum	Nitrofurantoin is actively transported into human milk, achieving concentrations in milk greatly exceeding those in serum.	Affirmed
26	found	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	insufficient	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	evidence	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	acupuncture	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	effective	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	controlling	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	menopausal symptoms	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	vasomotor	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	menopausal	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
26	symptoms vasomotor	We found insufficient evidence to determine whether acupuncture is effective for controlling menopausal vasomotor symptoms.	Affirmed
27	compared	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	acupuncture	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	s-ham	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	sham	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	no evidence of	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	significant	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	difference	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	in	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	effect	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	menopausal symptoms	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	vasomotor	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	menopausal	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
27	symptoms vasomotor	When we compared acupuncture with sham acupuncture, there was no evidence of a significant difference in their effect on menopausal vasomotor symptoms.	Affirmed
28	compared	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	acupuncture	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	treatment	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	appear	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	to	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	benefit	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	less than	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	effective	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
28	ht	When we compared acupuncture with no treatment there appeared to be a benefit from acupuncture, but acupuncture appeared to be less effective than HT.	Affirmed
29	findings	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	treated with	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	great	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	evidence	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	low	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	very low	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	quality	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	studies	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	compare	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	acupuncture	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	treatment	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	ht	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	not	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	controlled	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	s-ham	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	sham	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
29	placebo	These findings should be treated with great caution as the evidence was low or very low quality and the studies comparing acupuncture versus no treatment or HT were not controlled with sham acupuncture or placebo HT.	Affirmed
30	childhood	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	adhd	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	specific	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	adult disorders	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	psychiatric	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	adult	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	psychiatric disorders	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	antisocial	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
30	disorder, drug abuse	Childhood ADHD predicts specific adult psychiatric disorders, namely antisocial and drug abuse disorders.	Affirmed
31	in	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	adolescent	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	outcome	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	cohort	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	found	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	disturbance	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	dependent	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	adhd	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
31	symptoms	In the adolescent outcome of this cohort, we found that these disturbances were dependent on the continuation of ADHD symptoms.	Affirmed
32	contrast	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	adulthood	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	antisocial	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	drug	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	disorders	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	appear	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	part	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	sustained	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
32	adhd	In contrast, in adulthood, antisocial and drug disorders appeared, in part, independent of sustained ADHD.	Affirmed
33	addition	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	psychiatric	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	status	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	adhd	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	place	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	child at risk	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	relative	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	educational	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
33	vocation	In addition, regardless of psychiatric status, ADHD placed children at relative risk for educational and vocational disadvantage.	Affirmed
34	result	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	not	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	support	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	relationship	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	childhood	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	adhd	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	adult	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	mood	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
34	anxiety disorders	The results do not support a relationship between childhood ADHD and adult mood or anxiety disorders.	Affirmed
35	drugs	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	used	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	to	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	treat	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	pco	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	pcos	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	appear	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	associated with	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	very severe	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	low risk	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	adverse effects	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	data	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
35	population	Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.	Affirmed
36	patients	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	reported	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	greater	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	relief	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	symptoms	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	with	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	debacterol	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	kenalog	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	orabase	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
36	treatment	Patients subjectively reported significantly greater relief from symptoms with Debacterol than with Kenalog-in-Orabase or no treatment.	Affirmed
37	relief	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	symptoms	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	associated with	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	recurrent aphthous stomatitis	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	aphthous stomatitis, recurrent	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	not	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	clinical	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	improvement	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	two	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	topical	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	medications	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	affect	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	signs	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
37	lesions	The relief of symptoms associated with recurrent aphthous stomatitis may or may not correspond to clinical improvement, and these two topical medications may affect signs and symptoms of the lesions differently.	Affirmed
38	other prevention	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	pain finding	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	recommend	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	local anaesthetic	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	local anesthetic	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	administered	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	advance	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	circumcision	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	procedure	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	used	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
38	contraindicated	On the basis of these and other findings on pain prevention and amelioration, we recommend that a local anesthetic be administered in advance of circumcision and that the Mogen procedure be used, unless contraindicated.	Affirmed
39	recommend	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	infants	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	given	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	pacifier	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	and	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	circumcision	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	method	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
39	used	We also recommend that infants be given a sweetened pacifier before, during, and after circumcision if the Gomco method is used.	Affirmed
40	active	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	approach	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	diagnosis	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	management	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	precursor	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	lesions	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	often	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	prevent	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	development	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
40	cancer of the vulva	A more active approach to the diagnosis and management of precursor lesions may often prevent the development of vulvar cancer.	Affirmed
41	ankyloglossia	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	a population	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	common	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	newborn (finding)	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	represent	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	significant	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	proportion	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	breast feeding problems	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
41	breastfeeding problems	Ankyloglossia is a relatively common finding in the newborn population and represents a significant proportion of breastfeeding problems.	Affirmed
42	care	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	lingual	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	functional assessment	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	followed by	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	indicated	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	to	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	successful	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	approach	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	facilitation	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	breast feeding	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	in	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	presence	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	significant	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
42	ankyloglossia	Careful assessment of the lingual function, followed by frenuloplasty when indicated, seems to be a successful approach to the facilitation of breastfeeding in the presence of significant ankyloglossia.	Affirmed
43	ankyloglossia	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	a population	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	common	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	newborn (finding)	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	affect	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	breast feeding	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	select	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
43	infants	Ankyloglossia, which is a relatively common finding in the newborn population, adversely affects breastfeeding in selected infants.	Affirmed
44	antibiotic	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	topical	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	steroid	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	alone	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	combination	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	effective treatment	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	for	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	acute sinusitis	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	primary care	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
44	setting	Neither an antibiotic nor a topical steroid alone or in combination was effective as a treatment for acute sinusitis in the primary care setting.	Affirmed
45	currently	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	study	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	antidepressants	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	studies	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	for	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	treatment	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	agitation	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	psychosis	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	dementia	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
45	psychosis nos	Currently there are relatively few studies of antidepressants for the treatment of agitation and psychosis in dementia.	Affirmed
46	ssris	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	sertraline	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	citalopram	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	associated with	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	reduction	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	in	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	symptoms	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	agitation	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	compared	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	placebo	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	two	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
46	studies	The SSRIs sertraline and citalopram were associated with a reduction in symptoms of agitation when compared to placebo in two studies.	Affirmed
47	ssris	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	trazodone	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	appear	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	to	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	well	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	compared	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	placebo	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	typical antipsychotic	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
47	atypical antipsychotic	Both SSRIs and trazodone appear to be tolerated reasonably well when compared to placebo, typical antipsychotics and atypical antipsychotics.	Affirmed
48	future	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	studies	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	involving	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	more	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	subject	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	required	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	to	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	ssris	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	trazodone	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	antidepressants	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	effective treatment	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	agitation	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	psychosis	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	dementia	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
48	psychosis nos	Future studies involving more subjects are required to determine if SSRIs, trazodone, or other antidepressants are safe and effective treatments for agitation and psychosis in dementia.	Affirmed
49	evidence	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	suggest	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	mode of action	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	bupropion	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	nortriptyline	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	independent of	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	antidepressant	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	effect	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	are	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	similar	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	efficacy	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
49	nicotine replacement	Evidence suggests that the mode of action of bupropion and nortriptyline is independent of their antidepressant effect and that they are of similar efficacy to nicotine replacement.	Affirmed
50	evidence	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	suggest	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	bupropion	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	less than	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	effective	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	varenicline	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	further	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	research	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	needed	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	to	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	confirm	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
50	finding	Evidence also suggests that bupropion is less effective than varenicline, but further research is needed to confirm this finding.	Affirmed
51	atypical antipsychotic	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	use	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	associated with	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	increased	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	risk	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	death	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	death, nos	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	compared	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	older adult	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
51	dementia	Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia.	Affirmed
52	risk	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
52	death	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
52	death, nos	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
52	greater	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
52	conventional	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
52	antipsychotics	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
52	atypical antipsychotic	The risk for death may be greater with conventional antipsychotics than with atypical antipsychotics.	Affirmed
53	consistent	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	evidence	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	anxiolytics	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	aid	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	smoking cessation	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	available	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	not	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	rule	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	out	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	possible	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
53	effect	There is no consistent evidence that anxiolytics aid smoking cessation, but the available evidence does not rule out a possible effect.	Affirmed
54	review, systematic	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	present	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	information	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	relate	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	effectiveness	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	safety	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	intervention following	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	analgesics	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	local	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	carbenoxolone mouthwash	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	chlorhexidine	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	similar	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	agent	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	corticosteroids	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	topical	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	tetracycline	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	antibiotic	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	mouth wash	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
54	mouthwash	In this systematic review we present information relating to the effectiveness and safety of the following interventions: analgesics (local), carbenoxolone mouthwash, chlorhexidine (and similar agents), corticosteroids (topical), and tetracycline antibiotic mouthwash.	Affirmed
56	scale	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	reliability validity	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	accurate	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	measure	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	shoulder	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	function	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	in	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	patients	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	ra	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	completed	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
56	minute	The SFA Scale is a reliable, valid, and accurate measure of shoulder function in patients with RA that can be completed within 3 minutes.	Affirmed
57	meta	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	analyzed	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	more	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	new	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	research results	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	separated status	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	women	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	according	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	menopausal	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	separated	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	women's status	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	menopausal status	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	soy isoflavone	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	breast cancer	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	association	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	breast	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
57	cancer association	We meta-analyzed more and newer research results, and separated women according to menopausal status to explore soy isoflavone-breast cancer association.	Affirmed
58	found	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	soy isoflavone	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	intake	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	lower	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	risk	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	cancer of the breast	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	pre	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	post menopausal	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	women	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
58	asian countries	We founded that soy isoflavone intake could lower the risk of breast cancer for both pre- and post-menopausal women in Asian countries.	Affirmed
59	for	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	women	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	western	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	countries	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	pre	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	post menopausal	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	evidence	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	suggest	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	association	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	intake	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	soy isoflavone	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
59	breast cancer	However, for women in Western countries, pre- or post-menopausal, there is no evidence to suggest an association between intake of soy isoflavone and breast cancer.	Affirmed
60	majority	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	infants	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	wheezing	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	transient	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	condition	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	associated with	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	diminished	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	airway, nos	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	function	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	airway	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	birth	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	not	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	increased	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	risks	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	asthma	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	allergies	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	late	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
60	life	The majority of infants with wheezing have transient conditions associated with diminished airway function at birth and do not have increased risks of asthma or allergies later in life.	Affirmed
61	in	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	minority	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	infants	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	wheezing	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	episodes	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	probably	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	related	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	predisposition	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
61	asthma	In a substantial minority of infants, however, wheezing episodes are probably related to a predisposition to asthma.	Affirmed
62	one	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	continuous	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	auricular acupuncture	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	week	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	decrease	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	pain	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	pain nos	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	disability	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	experience	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	women	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	pregnancy related	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	low	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	back	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	posterior pain	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	pelvic	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	posterior	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	pelvic pain	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
62	pelvic pain, nos	One week of continuous auricular acupuncture decreases the pain and disability experienced by women with pregnancy-related low back and posterior pelvic pain.	Affirmed
63	based	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	findings	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	prior	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	studies	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	daily	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	aza	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	gel	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	effective	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	dose	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	treatment option	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	mild to moderate	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
63	papulopustular rosacea	Based on these findings and those of prior studies, once-daily AzA 15% gel can therefore be utilized as a safe, effective, and economical dosing option for the treatment of mild-to-moderate papulopustular rosacea.	Affirmed
64	daily	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	aza	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	gel	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	well	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	accepted	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	patients	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	dose	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	flexibility	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
64	dermatologist	Once-daily dosing of AzA 15% gel was well accepted by patients and can offer considerable dosing flexibility and convenience for the patient as well as for the dermatologist.	Affirmed
65	bioflavonoids	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
65	early	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
65	outcome	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
65	transplantation, renal	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
65	possibly	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
65	ho-1	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
65	induction	These bioflavonoids improve early outcomes in cadaveric renal transplantation, possibly through HO-1 induction.	Affirmed
66	conclude	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	management	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	rosacea	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	basic	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	skin care	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	regimens	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	including	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	daily	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	therapeutic use	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	optimal	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
66	benefits	It can thus be concluded that in the management of rosacea, basic skin care regimens, including daily use of a therapeutic moisturizer, offer optimal benefits.	Affirmed
67	randomized controlled clinical trial	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	placebo	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	lipid a	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	modify	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	agent	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	in	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	men	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	previous	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
67	myocardial infarction	The CDP was a randomized, placebo-controlled clinical trial of lipid-modifying agents in men with previous myocardial infarction (MI).	Affirmed
69	patients	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	treated with	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	niacin	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	n nos	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	placebo	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	grouped	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	according	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	presence	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	absence	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	ms	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
69	baseline	Patients treated with niacin (n = 1,119) and placebo (n = 2,787) were grouped according to the presence or absence of the MS at baseline.	Affirmed
70	ms	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	defined	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	basis	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	meeting	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	3 5	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	criteria	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	from	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	current	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	national	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	cholesterol	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	education of patients	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	program	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	guidelines	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	small	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	subgroup	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	with	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	high density lipoprotein cholesterol	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	determinations	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	baseline	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	and	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	3 4	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	total population	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	exclude	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
70	criterion	The MS was defined on the basis of meeting > or =3 of 5 criteria from the current National Cholesterol Education Program guidelines in a small subgroup of patients with high-density lipoprotein cholesterol determinations at baseline and on the basis of > or =3 of 4 criteria in the total population, excluding the high-density lipoprotein cholesterol criterion.	Affirmed
72	conclusion	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	result	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	support	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	use of	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	niacin	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	in	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	patients	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	and	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
72	ms	In conclusion, these results support the use of niacin in postinfarction patients with and without the MS.	Affirmed
73	study	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	demonstrates	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	used	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	conjunction	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	pacifier	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	dip	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	sucrose	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	more	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	comfortable	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	pad	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	physiologic	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	restraint	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	use	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	decreasing	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	distress	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	pain	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
73	pain nos	This study demonstrates that, when used in conjunction with DPNB, a pacifier dipped in 24% sucrose and a more comfortable, padded, and physiologic restraint can be useful in decreasing distress and pain.	Affirmed
74	uncertain	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	quality	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	identified	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	trial	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	need	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	improved	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	reporting	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	study	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	methods	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	allocation	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	handling	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	incomplete data	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
74	outcome	The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data.	Affirmed
75	effect	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	black cohosh	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	outcome	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	health quality of life	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	related	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	sexuality	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	bone	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	health	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	night sweats	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	cost effectiveness	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	further	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
75	investigation	The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.	Affirmed
76	present	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	time	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	evidence	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	randomized trial	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	not	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	support	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	blood pressure	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	target	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	lower	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	standard	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	in	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	people	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	elevated blood pressure	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
76	diabetes	At the present time, evidence from randomized trials does not support blood pressure targets lower than the standard targets in people with elevated blood pressure and diabetes.	Affirmed
77	more	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	randomized controlled trials	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	needed	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	future	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	trial	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	reporting	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	mortality	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	total	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	serious adverse event	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	cardiovascular	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	renal	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
77	events	More randomized controlled trials are needed, with future trials reporting total mortality, total serious adverse events as well as cardiovascular and renal events.	Affirmed
79	problems	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	standardization	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	safety	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	concerns	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	limit	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	applicable	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	clinical	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
79	practice	However, problems with standardization and safety concerns may limit their applicability in clinical practice.	Affirmed
80	whole	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	grain intake	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	attribute	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	cereal	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	fiber	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	associated with	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	ir	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	lower	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	prevalence	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
80	metabolic syndrome	Whole-grain intake, largely attributed to the cereal fiber, is inversely associated with HOMA-IR and a lower prevalence of the metabolic syndrome.	Affirmed
81	dietary	Dietary glycemic index is positively associated with HOMA-IR and prevalence of the metabolic syndrome.	Affirmed
81	glycemic index	Dietary glycemic index is positively associated with HOMA-IR and prevalence of the metabolic syndrome.	Affirmed
81	associated with	Dietary glycemic index is positively associated with HOMA-IR and prevalence of the metabolic syndrome.	Affirmed
81	ir	Dietary glycemic index is positively associated with HOMA-IR and prevalence of the metabolic syndrome.	Affirmed
81	prevalence	Dietary glycemic index is positively associated with HOMA-IR and prevalence of the metabolic syndrome.	Affirmed
81	metabolic syndrome	Dietary glycemic index is positively associated with HOMA-IR and prevalence of the metabolic syndrome.	Affirmed
82	given	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	high	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	cereal	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	fiber	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	content	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	lower	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	glycemic index	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	attribute	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	whole food	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	grain	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	recommendation to	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	increase	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	whole	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	grain intake	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	risk	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
82	metabolic syndrome	Given that both a high cereal fiber content and lower glycemic index are attributes of whole-grain foods, recommendation to increase whole-grain intake may reduce the risk of developing the metabolic syndrome.	Affirmed
83	results study	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	intake	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	<3	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	cinnamon	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	day	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	serum glucose	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	triglyceride	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	cholesterol, ldl	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	ldl cholesterol	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	total cholesterol	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	people	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	type 2 diabetes	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	suggest	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	inclusion	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	in	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	diet	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	risk factors	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	associated with	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	diabetes	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
83	cardiovascular diseases	The results of this study demonstrate that intake of 1, 3, or 6 g of cinnamon per day reduces serum glucose, triglyceride, LDL cholesterol, and total cholesterol in people with type 2 diabetes and suggest that the inclusion of cinnamon in the diet of people with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular diseases.	Affirmed
84	use of	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	cinnamon	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	show	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	effect	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	glycemia	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	control	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	short-term	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	months	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	effects	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	looks	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
84	promise	Use of cinnamon showed a beneficial effect on glycaemic control (both HbA1c and FPG) and the short term (<4 months) effects of the use of cinnamon on glycaemic control looks promising.	Affirmed
85	brief intervention	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	increase	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	patients	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	health care providers	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	behavioral	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	goals	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	providers	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	behavioral health care	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	physical activity, increased	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	lead	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	weightloss	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
85	weight loss	A brief intervention to increase the dialogue between patients and health care providers about behavioral goals can lead to increased physical activity and weight loss.	Affirmed
86	combined therapy	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	tfg	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	sulfonylureas	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	hypoglycaemic drug, nos	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	lower	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	blood glucose level	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	clinical treatment	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	symptoms	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
86	therapy	The combined therapy of TFGs with sulfonylureas hypoglycemic drug could lower the blood glucose level and ameliorate clinical symptoms in the treatment of T2DM, and the therapy was relatively safe.	Affirmed
87	prophylaxis	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	initiation	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	chronic gouty arthritis	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	frequency	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	severity	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	acute	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	flare	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	likelihood	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
87	recurrent	Colchicine prophylaxis during initiation of allopurinol for chronic gouty arthritis reduces the frequency and severity of acute flares, and reduces the likelihood of recurrent flares.	Affirmed
88	treating	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	patients	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	colchicine	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	during	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	initiation	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	allopurinol	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	therapy	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	months	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	supported	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
88	data	Treating patients with colchicine during initiation of allopurinol therapy for 6 months is supported by our data.	Affirmed
89	blood pressure drugs	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	reduction	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	combine	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	class	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	predicted	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	basis	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	additive	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
89	effects	Blood pressure reduction from combining drugs from these 4 classes can be predicted on the basis of additive effects.	Affirmed
90	blood pressure drugs	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	reduction	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	combine	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	2 class	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	different	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	approximately	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	times	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	greater than	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	doubling	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
90	drug dose	The extra blood pressure reduction from combining drugs from 2 different classes is approximately 5 times greater than doubling the dose of 1 drug.	Affirmed
91	combination	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	curcumin	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	quercetin	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	appear	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	to	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	number	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	size	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	ileal	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	rectal adenoma	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	patients	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	with	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
91	toxicity	The combination of curcumin and quercetin appears to reduce the number and size of ileal and rectal adenomas in patients with FAP without appreciable toxicity.	Affirmed
92	prednisolone 1 mg	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	kg	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	low dose	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	dexamethasone	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	low-dose	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	mg kg	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	found	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	not	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	efficacy	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	currently	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
92	recommended	Both prednisolone 1 mg/kg and low-dose dexamethasone (0.15 mg/kg) were found not to differ in efficacy from the currently recommended 0.6 mg/kg dexamethasone.	Affirmed
93	corticosteroid use	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	regimens	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	in	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	treating	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	patients	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	mild to moderate	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	croup	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
93	supported	The use of these corticosteroid regimens in treating patients with mild to moderate croup is thus supported.	Affirmed
94	main	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	overall	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	finding	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	study	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	saffron	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	be	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	therapeutic	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	benefit	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	in	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	treatment	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	mild to moderate	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	depression	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
94	depression nos	The main overall finding from this study is that saffron may be of therapeutic benefit in the treatment of mild to moderate depression.	Affirmed
95	to	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	best	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	knowledge	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	first	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	clinical trial	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	support	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	this	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	indication	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
95	saffron	To the best of our knowledge this is the first clinical trial that supports this indication for saffron.	Affirmed
96	vitamin supplementation	Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies.	Affirmed
96	well	Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies.	Affirmed
96	daily	Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies.	Affirmed
96	weekly	Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies.	Affirmed
96	monthly	Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies.	Affirmed
96	dosing frequency	Supplementation with vitamin D can be achieved equally well with daily, weekly, or monthly dosing frequencies.	Affirmed
97	choice	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	dose frequency	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	based	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	approach	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	individual	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	adherence	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	long-term	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	vitamin d	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
97	supplementation	Therefore, the choice of dose frequency can be based on whichever approach will optimize an individual's adherence with long-term vitamin D supplementation.	Affirmed
98	study	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
98	azithromycin	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
98	effective	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
98	doxycycline	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
98	in	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
98	treatment	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
98	rosacea	This study indicates that azithromycin is at least as effective as doxycycline in the treatment of rosacea.	Affirmed
99	recommendation	It is our recommendation that an anesthetic should be administered to newborns prior to undergoing circumcision.	Affirmed
99	anaesthetic	It is our recommendation that an anesthetic should be administered to newborns prior to undergoing circumcision.	Affirmed
99	administered	It is our recommendation that an anesthetic should be administered to newborns prior to undergoing circumcision.	Affirmed
99	newborns	It is our recommendation that an anesthetic should be administered to newborns prior to undergoing circumcision.	Affirmed
99	circumcision	It is our recommendation that an anesthetic should be administered to newborns prior to undergoing circumcision.	Affirmed
100	behavioral therapy	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	greater	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	patient result	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	satisfaction	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	result	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	patient satisfaction	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	few	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	incontinence	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	symptoms	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	pessary	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	3 months	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	difference	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	not	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
100	months	Behavioral therapy resulted in greater patient satisfaction and fewer bothersome incontinence symptoms than pessary at 3 months, but differences did not persist to 12 months.	Affirmed
101	electron beam	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	ct	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	coronary calcium score	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	events	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	independent of	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	standard	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	risk factors	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	more	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	cleanse	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	purified	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	framingham	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	risk	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
101	stratification	The electron beam CT coronary calcium score predicts CAD events independent of standard risk factors, more accurately than standard risk factors and CRP, and refines Framingham risk stratification.	Affirmed
102	female	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
102	diabetic	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
102	neurophysiology	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
102	confirmation of	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
102	diagnosis	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
102	high risk of	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
102	relapse	Those who are female, diabetic and have neurophysiological confirmation of diagnosis have the highest risk of relapse.	Affirmed
103	corticosteroids	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	provide	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	symptomatic relief	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	pain	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	pain nos	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	symptomatic	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	pain relief	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	sore throat	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	sorethroat	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	antibiotic therapy	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	participants	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	severe	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
103	exudative sore throat	Corticosteroids provide symptomatic relief of pain in sore throat, in addition to antibiotic therapy, mainly in participants with severe or exudative sore throat.	Affirmed
104	disorders	There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids.	Affirmed
104	to	There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids.	Affirmed
104	benefit	There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids.	Affirmed
104	fatty acid	There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids.	Affirmed
104	supplementation	There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids.	Affirmed
104	omega-3 fatty acids	There are a myriad of disorders and maladies that seem to benefit from fatty acid supplementation, specifically omega-3 fatty acids.	Affirmed
105	show	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	omega 3 fatty acid supplementation	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	provides	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	provide	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	benefit	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	heart disease	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	and	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
105	sudden cardiac death	It has clearly been shown that omega-3 fatty acid supplementation provides a protective benefit in heart disease, and in particular sudden cardiac death.	Affirmed
106	rheumatoid arthritis	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	disease	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	entity	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	proven	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	to	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	benefit	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	nutrition intervention	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	with	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	improvement	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	symptoms	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	diminished	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	non-steroidal anti-inflammatory drug	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
106	usage	Rheumatoid arthritis (RA) is another disease entity that has been proven to benefit from this nutrition intervention, with improvement in symptoms and diminished nonsteroidal antiinflammatory drug (NSAID) usage.	Affirmed
107	addition	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	psychiatric disorders	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	schizophrenia	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	major depressive disorder	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	show	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	result	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	positive	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	supplementation	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	used	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	standard	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
107	pharmacotherapy	In addition, many psychiatric disorders, particularly schizophrenia and major depressive disorder (MDD), have shown positive results when supplementation has been used as an adjunct to standard pharmacotherapy.	Affirmed
108	preliminary	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
108	clinical	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
108	evidence	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
108	parenteral administration	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
108	fatty acids	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
108	further	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
108	study	Specifically, according to preliminary clinical evidence, parenteral administration of fatty acids warrants further study.	Affirmed
109	predictive	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	nomogram	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	six	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	variables	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	easily	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	first prenatal visit	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	allow	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	determination	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	specific	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	chance	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	for	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	successful	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	vbac	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	women	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
109	trial of labor	A predictive nomogram, which incorporates six variables easily ascertainable at the first prenatal visit, has been developed that allows the determination of a patient-specific chance for successful VBAC for those women who undertake trial of labor.	Affirmed
110	smokers	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	lung function	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	to	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	modify	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	habit	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	screening result	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	copd nos	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	combined	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
110	smoking cessation advice	All smokers, irrespective of their lung function, tried to modify their habit as the result of screening for COPD combined with smoking cessation advice.	Affirmed
111	old age	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
111	lower	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
111	tobacco exposure	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
111	lung function	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
111	predictor	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
111	success	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
111	quitting smoking	Older age, lower tobacco exposure, and lower lung function were the predictors of success in quitting smoking.	Affirmed
112	inverse association	DDS had inverse association with metabolic syndrome and some of its features in this cross-sectional study.	Affirmed
112	metabolic syndrome	DDS had inverse association with metabolic syndrome and some of its features in this cross-sectional study.	Affirmed
112	some	DDS had inverse association with metabolic syndrome and some of its features in this cross-sectional study.	Affirmed
112	feature	DDS had inverse association with metabolic syndrome and some of its features in this cross-sectional study.	Affirmed
112	cross-sectional study	DDS had inverse association with metabolic syndrome and some of its features in this cross-sectional study.	Affirmed
113	high	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
113	dietary	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
113	diversity	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
113	associated with	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
113	lower	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
113	possible	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
113	metabolic disorders	A higher dietary diversity, therefore, might be associated with lower possibility of having some metabolic disorders.	Affirmed
114	significant	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	associations	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	exist	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	dietary patterns	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	identified	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	analysis, factor	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	metabolic syndrome	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
114	insulin resistance	Significant associations exist between dietary patterns identified by factor analysis, the metabolic syndrome, and insulin resistance.	Affirmed
115	evidence	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	promise	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	treatment effect	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	omega-3 fatty acids	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	for	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	depression	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	adults	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	depression nos	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	definitive	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	clinical statement	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	efficacy	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
115	premature	The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a statement of definitive clinical efficacy is premature.	Affirmed
116	further	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	study	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	fatty acids, essential	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	independent	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	adjuvant therapy	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	adult	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	depression	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	depression nos	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	indicated	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	including	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	more	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	investigation	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	dose	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	response	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
116	population	Further study of essential fatty acids as independent and adjuvant therapy for adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.	Affirmed
117	high	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	levels	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	parental	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	smoking	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	home	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	associated with	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	reduction	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	in care	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	health	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	contact	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	asthma	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	in	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
117	asthma care	High levels of parental smoking in the home are associated with a reduction in health care contacts for asthma.	Affirmed
118	be	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	due to	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	lack of awareness	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	asthma	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	symptoms	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	heavy	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	smokers	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	reluctance	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
118	visit	This could be due to a lack of awareness of asthma symptoms among heavy smokers or a reluctance to visit the GP.	Affirmed
119	sonography	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	needle	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	guidance	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	performance	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	out-patient	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	ia	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	injection outcome	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	outpatient	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
119	significant	Sonographic needle guidance significantly improves the performance and outcomes of outpatient IA injections in a clinically significant manner.	Affirmed
120	sports activity	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	adolescents	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	adults, young	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	associated with	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	increased	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	risk	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	both	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	males	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
120	females	Sports activity in adolescents and young adults was associated with an increased risk of SD, both in males and females.	Affirmed
121	sports	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	not	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	cause	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	enhanced	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	mortality	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	trigger	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	athletes	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	affected	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	cardiovascular condition	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	predisposing	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	life threatening	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	ventricular arrhythmias	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
121	exercise, physical	Sports, per se, was not a cause of the enhanced mortality, but it triggered SD in those athletes who were affected by cardiovascular conditions predisposing to life-threatening ventricular arrhythmias during physical exercise.	Affirmed
122	ulcer	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	area	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	larger	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	cm2	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	positive test result	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	probe	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	bone	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	erythrocyte sedimentation rate	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	abnormal result	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	plain radiography	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	help	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	diagnosing	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	presence	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	lower extremity	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	osteomyelitis	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	in	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	patients	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
122	diabetes	An ulcer area larger than 2 cm2, a positive probe-to-bone test result, an erythrocyte sedimentation rate of more than 70 mm/h, and an abnormal plain radiograph result are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes.	Affirmed
123	several	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	individual	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	clinical feature	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	found	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	to	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	associated with	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	significant	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	intracranial	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	abnormality	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	patient feature	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
123	neuroimaging	Several individual clinical features were found to be associated with a significant intracranial abnormality, and patients with these features should undergo neuroimaging.	Affirmed
124	guide	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	arthrocentesis	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	injection of knee	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	superior	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	landmark, anatomic	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	palpation	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	resulting in	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	procedures	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	pain	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	pain nos	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	procedure	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	improved	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	success	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	greater	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	synovial fluid	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	more	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	complete	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	joint	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	decompression	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	joint, nos	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	clinical	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
124	outcome	US-guided arthrocentesis and injection of the knee are superior to anatomic landmark palpation-guided arthrocentesis, resulting in significantly less procedural pain, improved arthrocentesis success, greater synovial fluid yield, more complete joint decompression, and improved clinical outcomes.	Affirmed
125	in	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	over weight	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	obese	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	adolescents	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	pco	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	pcos	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	months	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	treatment	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	rosiglitazone	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	superior	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	drospirenone	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	improving	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	risk	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	profile	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	effective	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	inferior	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	attenuate	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
125	hyperandrogenemia	In overweight/obese adolescents with PCOS, 6 months treatment with rosiglitazone was superior to drospirenone/EE in improving the cardiometabolic risk profile, and effective but inferior in attenuating hyperandrogenemia.	Affirmed
126	additional	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	studies	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	needed	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	to	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	test	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	treatment insulin	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	reproductive	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	insulin treatment	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	aspect	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	pco	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
126	pcos	Additional studies are needed to test insulin sensitizers in the treatment of the reproductive and cardiometabolic aspects of PCOS.	Affirmed
127	result	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	drug-induced	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	suppression	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	phk	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	activity	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	associated with	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	resolution	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	assessed	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	clinical	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	histological	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	immunohistochemical	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	criteria	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	support	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	hypothesis	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	effective	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	antipsoriatic	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
127	modulation	Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.	Affirmed
128	statin	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	early therapy	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	reduction	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	leads	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	lead	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	in	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	clinical events day	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	consistent with	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	greater	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	early	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
128	effects	Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects.	Affirmed
129	stable	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	patients	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	statin	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	therapy	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	provides	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	provide	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	long-term	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	reduction	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	clinical events	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	compared	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
129	standard therapy	In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy.	Affirmed
130	patients	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	started	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	in	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	hospital, nos	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	hospital	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	continued	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	long-term	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	statin	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
130	therapy	Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.	Affirmed
131	diagnostic	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	performance	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	sensitive	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	cardiac troponin	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	assay	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	excellent	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	early diagnosis	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	acute myocardial infarction	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	patients	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	with onset	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	recent	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
131	pain of breast	The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays can substantially improve the early diagnosis of acute myocardial infarction, particularly in patients with a recent onset of chest pain.	Affirmed
132	asthmatic	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	heredity	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	early	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	life	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	atopic predisposition	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	plus	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	passive smoke exposure	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	recurrent chest infection	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	influential	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	occurrence	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	wheeze	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	asthma	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
132	age-years	Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age.	Affirmed
133	bhr	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	age-years	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	risk	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	profile	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	suggest	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	factor	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	wheezing symptom	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	expression	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
133	predisposing	BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	Affirmed
134	present	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	study	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	suggest	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	childhood	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	adhd	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	specific	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	continue	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	to	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	affect	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	functional	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	domain	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	unrelated	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	current	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
134	diagnosis, psychiatric	The present study suggests that childhood ADHD predisposes to specific disadvantages and continues to affect important functional domains unrelated to current psychiatric diagnosis.	Affirmed
135	findings	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	adhd	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	associated with	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	significant	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	educational	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	occupational	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	relative	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	expected	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	basis	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
135	potential	These findings indicate that ADHD is associated with significant educational and occupational underattainments relative to what would have been expected on the basis of intellectual potential.	Affirmed
136	analysis	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	consistent with	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	prior	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	reports	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	show	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	ace inhibitors	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	decrease	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	risk	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	death	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	death, nos	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	following	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	recent	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	reducing	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	cardiovascular	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
136	mortality	This analysis is consistent with prior reports showing that ACE inhibitors decrease the risk of death following a recent MI by reducing cardiovascular mortality.	Affirmed
137	analysis	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
137	suggest	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
137	risk reduction	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
137	ace inhibitors	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
137	component	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
137	survival	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
137	benefit	Moreover, this analysis suggests that a reduction in SCD risk with ACE inhibitors is an important component of this survival benefit.	Affirmed
138	women	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	cholecystectomy	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	perception	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	constipation	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	leads	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	lead	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	slightly	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	frequent defecations	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	short-term	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	show	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	no change	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	consistent	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
138	bowel function	In women, cholecystectomy leads to the perception of less constipation and slightly more frequent defecations but short term recordings show no consistent change in bowel function.	Affirmed
139	no effect	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	significant	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	chromium	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	lipid	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	glucose metabolism	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	found	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	people	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
139	diabetes	No significant effect of chromium on lipid or glucose metabolism was found in people without diabetes.	Affirmed
140	future	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	study	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	studies	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	address	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	limitations	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	current	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	evidence	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	needed	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	definitive	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	make	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	effect	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	chromium	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
140	supplementation	However, future studies that address the limitations in the current evidence are needed before definitive claims can be made about the effect of chromium supplementation.	Affirmed
141	percentage	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	oxalate	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	water	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	soluble	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	markedly	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	cinnamon	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	turmeric	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	appear	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	to	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	primary	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	cause	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	greater	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	urinary excretion	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
141	absorption	The percentage of oxalate that was water soluble differed markedly between cinnamon (6%) and turmeric (91%), which appeared to be the primary cause of the greater urinary oxalate excretion/oxalate absorption from turmeric.	Affirmed
142	consumption	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	supplemental	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	doses	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	turmeric	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	not	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	cinnamon	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	increase	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	urinary levels	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	oxalate	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	increasing	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	risk	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	kidney stone	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	formation	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	stone, kidney	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	susceptible	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
142	individual	The consumption of supplemental doses of turmeric, but not cinnamon, can significantly increase urinary oxalate levels, thereby increasing risk of kidney stone formation in susceptible individuals.	Affirmed
143	behavior child problems	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	emotional	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	wet	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	beds	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	need	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	not	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	first	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	treated	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	behavioral problems	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	behavioral	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
143	emotional problems	Children with behavioural/emotional problems who wet their beds need not first be treated for their behavioural/emotional problems.	Affirmed
144	bed wetting	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	treated	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	dbt	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	other treatments	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	normal	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	alarm	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	failed	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	treatment	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	behavior influence	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	emotional problems	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
144	positive	Bedwetting can be treated successfully with DBT when other treatments such as normal alarm treatment have failed, and alarm treatment/DBT can have a positive influence on behavioural/emotional problems.	Affirmed
145	data	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	show	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	budesonide	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	inhaled	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	months	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	not	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	cause	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	significant	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	improvement	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	bhr	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	adolescents	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	long-term	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	asthma	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
145	remission	Our data have shown that budesonide inhaled regularly for 9 months did not cause a significant improvement in the BHR of adolescents with long-term asthma remission.	Affirmed
146	suggest	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
146	mechanism	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
146	bhr	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
146	clinical setting	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
146	different	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
146	symptomatic	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
146	asthma	This suggests that the mechanism underlying BHR in this clinical setting may be different from that in symptomatic asthma.	Affirmed
147	treatment	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	exercise	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	systolic bp	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	mmhg	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	mean	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	patients	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	randomized	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	losartan	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	received	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
147	hctz	Before treatment, exercise systolic BP was 213 +/- 13 mm Hg (mean +/- SD) in the 19 patients randomized to losartan and 209 +/- 11 mm Hg in the 21 patients who received HCTZ.	Affirmed
148	months	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	exercise	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	systolic bp	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	reduced	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	patients	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	received	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	losartan	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	23	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	mmhg	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	p nos	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	p'	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
148	hctz	After 6 months, exercise systolic BP was similarly reduced in patients who received losartan (197 +/- 23 mm Hg, p < 0.01) and HCTZ (191 +/- 11 mm Hg, p < 0.01).	Affirmed
149	losartan	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	treadmill	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	exercise time	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	increased	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	seconds	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	p nos	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	p'	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	quality of life	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	improved	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	without	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	change	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	oxygen consumption	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	min 1	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
149	p-30	With losartan, treadmill exercise time increased from 894 +/- 216 to 951 +/- 225 seconds (p = 0.011), and quality of life improved from 15 +/- 12 to 7 +/- 10 (p = 0.015) without a change in oxygen consumption (1,895 +/- 470 to 1,954 +/- 539 ml/min, p = 0.30).	Affirmed
150	hctz	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	exercise time	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	seconds	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	p-32	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	quality of life	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	p nos	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	p'	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	not	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	change	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	oxygen consumption	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
150	decreased	With HCTZ, exercise time (842 +/- 225 to 872 +/- 239 seconds, p = 0.32) and quality of life (19 +/- 21 vs 19 +/- 24, p = 0.43) did not change, whereas oxygen consumption decreased from 2,144 +/- 788 to 1,960 +/- 706 ml/min (p = 0.022).	Affirmed
151	conclusion	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	in	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	patients	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	diastolic dysfunction	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	hypertensive	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	responses	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	exercise	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	months	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	losartan	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	hctz	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	blunted	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
151	systolic bp	In conclusion, in patients with diastolic dysfunction and hypertensive responses to exercise, 6 months of losartan and HCTZ blunted systolic BP during exercise.	Affirmed
152	moderate	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	caffeine reduction	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	intake	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	in	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	second pregnancy	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	half	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	no effect	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	birth weight	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
152	length of gestation	A moderate reduction in caffeine intake in the second half of pregnancy has no effect on birth weight or length of gestation.	Affirmed
153	smokers	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	lung	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	age	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	likelihood	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	quitting smoking	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	mechanism	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	intervention	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
153	effect	Telling smokers their lung age significantly improves the likelihood of them quitting smoking, but the mechanism by which this intervention achieves its effect is unclear.	Affirmed
154	review	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	found	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	support	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	use of	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	systemic	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	aciclovir	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	valaciclovir	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
154	prevention	This review found support for the use of systemic acyclovir and valacyclovir for the prevention of RHL.	Affirmed
155	insufficient	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	scientific	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	evidence	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	conclude	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	maternity	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	support belt	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	pregnancy related	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	low back pain	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
155	pelvic girdle pain	There is insufficient scientific evidence to conclude that wearing maternity support belts reduces pregnancy-related low back pain and/or pelvic girdle pain.	Affirmed
156	relevance	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	clinical	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	practice	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	review	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	provides	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	provide	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	comprehensive	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	understanding	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	effectiveness	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	maternity	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	support belt	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	for	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	low	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	back of	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	pain relief	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	pregnancy	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	professionals	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	evidence-based health care	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	advice	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
156	patients	RELEVANCE TO CLINICAL PRACTICE: This review provides comprehensive understanding of the effectiveness of maternity support belts for the relief of low back pain during pregnancy which will facilitate healthcare professionals in providing evidence-based advice to their patients.	Affirmed
157	low	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	impact	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	exercise, aerobic	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	increasing	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	intensity	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	duration	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	frequency	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	effective	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	strategy	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	reducing	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	fatigue	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	in	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	adults	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	chronic condition	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	auto	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	immune	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	chronic	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
157	immune condition	Low impact aerobic exercise gradually increasing in intensity, duration and frequency may be an effective strategy in reducing fatigue in some adults with chronic auto-immune conditions.	Affirmed
158	fatigue	However, fatigue is a variable and personal experience and a range of behavioural interventions may be required.	Affirmed
158	variable	However, fatigue is a variable and personal experience and a range of behavioural interventions may be required.	Affirmed
158	personal experience	However, fatigue is a variable and personal experience and a range of behavioural interventions may be required.	Affirmed
158	range	However, fatigue is a variable and personal experience and a range of behavioural interventions may be required.	Affirmed
158	behavioral interventions	However, fatigue is a variable and personal experience and a range of behavioural interventions may be required.	Affirmed
158	required	However, fatigue is a variable and personal experience and a range of behavioural interventions may be required.	Affirmed
159	well	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	design	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	studies	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	testing	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	promise	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	strategies	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	consensus	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	outcome measures	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	fatigue	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
159	needed	Well-designed studies testing these promising strategies and consensus on outcome fatigue measures are needed.	Affirmed
160	two	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	treatments	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	applied	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	similar	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	effectiveness	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	relieving pain	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	reduced	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	size	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
160	recurrent aphthous ulcers	The two treatments applied had similar effectiveness as they both relieved pain and reduced the size of recurrent aphthous ulcers.	Affirmed
161	cinnamon extract	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	to	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	moderate	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	effect	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	reducing	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	fasting glucose plasma	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	concentrations	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	in	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	diabetic	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	patients	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
161	poor glycaemic control	The cinnamon extract seems to have a moderate effect in reducing fasting plasma glucose concentrations in diabetic patients with poor glycaemic control.	Affirmed
162	lupus erythematosus, systemic	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	self-management	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	course	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	self management	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	systemic lupus erythematosus	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	effects	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	reducing	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	fatigue	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	depression	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	depression nos	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	improving	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	coping skills	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
162	self efficacy	The systemic lupus erythematosus self-management course had effects in reducing fatigue and depression and improving coping skills and self-efficacy.	Affirmed
163	antiplatelet agent	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
163	clopidogrel	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
163	effects	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
163	patients	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
163	with	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
163	syndromes, acute coronary	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
163	st segment elevation	The antiplatelet agent clopidogrel has beneficial effects in patients with acute coronary syndromes without ST-segment elevation.	Affirmed
164	months	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	persons	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	pre-hypertension	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	stage 1	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	hypertension	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	sustain	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	multiple	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	lifestyle modification	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	control of blood pressure	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	risk	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	chronic disease	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	chronic	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
164	disease risk	Over 18 months, persons with prehypertension and stage 1 hypertension can sustain multiple lifestyle modifications that improve control of blood pressure and could reduce the risk for chronic disease.	Affirmed
165	trial	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	not	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	effect	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	daily	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	oral	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	dhea	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	fatigue	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	well-being	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	treatment	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	recommended	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	female patients	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
165	sle nos	The trial does not indicate an effect of daily 200 mg oral DHEA on fatigue and well-being, and therefore DHEA treatment is not recommended in unselected female patients with quiescent SLE.	Affirmed
166	doses	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	study	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	febuxostat	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	lowered	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	maintained	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	serum urate level	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	mg dl	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	allopurinol	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	placebo	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	subject	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	hyperuricaemia	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	gout	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	including	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	mild	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	moderately	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
166	impaired renal function	At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately impaired renal function.	Affirmed
167	habitual	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	diet	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	consumption	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	test	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	decreased food	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	gl	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	food consumption	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	decreased	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	not	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	metabolic	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	markers, risk	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	over weight	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
167	subject	When incorporated into a habitual diet, consumption of test foods with a decreased GL does not ameliorate metabolic risk markers in overweight subjects.	Affirmed
168	trial	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	evidence	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	effects	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	pufa	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	depressed mood	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	limited	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	difficult	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	evaluate	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
168	heterogeneity	Trial evidence that examines the effects of n-3 PUFAs on depressed mood is limited and is difficult to summarize and evaluate because of considerable heterogeneity.	Affirmed
169	twice daily	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	doxycycline	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	treatment	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	reduced	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	inflammatory	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	number	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	noninflammatory	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	lesions	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	patients	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	moderate	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	facial	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	acne	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	well	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	no effect	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	antimicrobial	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	skin	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	no	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	antimicrobial effect	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	not	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	result	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	increase	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	severity	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
169	resistant organism	Twice-daily SD doxycycline treatment significantly reduced the number of inflammatory and noninflammatory lesions in patients with moderate facial acne, was well tolerated, had no detectable antimicrobial effect on the skin flora, and did not result in any increase in the number or severity of resistant organisms.	Affirmed
170	present	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	analysis	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	provides	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	provide	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	estimate	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	average	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	treatment	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	testosterone	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	therapy effect	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	middle aged	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
170	men	The present analysis provides an estimate of the average treatment effects of testosterone therapy in middle-aged men.	Affirmed
171	findings	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	strong	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	justify	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	further	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	interventional study	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	focused	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	alternative	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	target	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	androgen	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	treatment	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	carrying	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	more	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	clinical	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	cardiovascular	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	metabolic	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	neurological	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
171	system	Our findings are sufficiently strong to justify further interventional studies focused on alternative targets of androgenic treatment carrying more stringent clinical implications, in particular the cardiovascular, metabolic and neurological systems.	Affirmed
172	ibuprofen	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	more	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	efficacy	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	acetaminophen	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	for	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	treatment pain	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	fever	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	adult	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	paediatric	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	population	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
172	pediatric	Ibuprofen is as or more efficacious than acetaminophen for the treatment of pain and fever in adult and pediatric populations and is equally safe.	Affirmed
173	controlled study	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	show	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	significant	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	short-term	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	efficacy	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	carbamazepine	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	carbamazepin	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	for	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	agitation	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	good	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	safety	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
173	tolerability	This controlled study showed significant short-term efficacy of carbamazepine for agitation with generally good safety and tolerability.	Affirmed
174	patients	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	chronic gout	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	elevated	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	serum uric acid level	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	allopurinol	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	intolerance	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	refractory	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	use of	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	pegloticase	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	2 weeks	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	every 4 weeks	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	months	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	every 4 months	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	weeks	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	result	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	lower	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	uric acid	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	levels	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	compared	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
174	placebo	Among patients with chronic gout, elevated serum uric acid level, and allopurinol intolerance or refractoriness, the use of pegloticase 8 mg either every 2 weeks or every 4 weeks for 6 months resulted in lower uric acid levels compared with placebo.	Affirmed
175	oral dexamethasone	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	dose	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	mg kg	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	effective	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	reducing	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	return	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	to	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	medical care	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	ongoing	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	croup	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	in	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	children	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
175	mild	Oral dexamethasone in a dose of 0.15 mg/kg is effective in reducing return to medical care with ongoing croup in children with mild croup.	Affirmed
176	dilute	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	alcohol	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	injection	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	effective treatment	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	option	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	patients	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	effective	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	treatment option	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	morton neuroma	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	to	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	surgical procedure	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	associated	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
176	complications	Dilute alcohol injection is a safe and effective treatment option for patients with Morton's neuroma who want to avoid a surgical procedure and any associated complications.	Affirmed
177	study	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
177	confirm	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
177	effects	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
177	plasma glucose	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
177	cholesterol levels	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
177	patients	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
177	type 2 diabetes	This study confirms the beneficial effects of Caiapo on plasma glucose as well as cholesterol levels in patients with type 2 diabetes.	Affirmed
178	first	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	time	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	long-term	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	efficacy	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	glucose control	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	observed	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	decrease	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
178	hba	For the first time, the long-term efficacy of Caiapo on glucose control was demonstrated by the observed decrease in HbA(1c).	Affirmed
179	immediate	We demonstrated immediate improvement in nipple-pain and breastfeeding scores, despite a placebo effect on nipple pain.	Affirmed
179	improvement	We demonstrated immediate improvement in nipple-pain and breastfeeding scores, despite a placebo effect on nipple pain.	Affirmed
179	nipple pain	We demonstrated immediate improvement in nipple-pain and breastfeeding scores, despite a placebo effect on nipple pain.	Affirmed
179	breast feeding	We demonstrated immediate improvement in nipple-pain and breastfeeding scores, despite a placebo effect on nipple pain.	Affirmed
179	scores	We demonstrated immediate improvement in nipple-pain and breastfeeding scores, despite a placebo effect on nipple pain.	Affirmed
179	placebo effect	We demonstrated immediate improvement in nipple-pain and breastfeeding scores, despite a placebo effect on nipple pain.	Affirmed
180	provide	This should provide convincing evidence for those seeking a frenotomy for infants with signficant ankyloglossia.	Affirmed
180	evidence	This should provide convincing evidence for those seeking a frenotomy for infants with signficant ankyloglossia.	Affirmed
180	infants	This should provide convincing evidence for those seeking a frenotomy for infants with signficant ankyloglossia.	Affirmed
180	ankyloglossia	This should provide convincing evidence for those seeking a frenotomy for infants with signficant ankyloglossia.	Affirmed
181	hpv vaccine	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	prevent	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	prevents	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	infection, nos	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	hpv-6	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	development	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	related	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	external	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	origin of lesion	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	males	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
181	age, in years	Quadrivalent HPV vaccine prevents infection with HPV-6, 11, 16, and 18 and the development of related external genital lesions in males 16 to 26 years of age.	Affirmed
182	elevated	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	troponin	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	level	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	stroke, acute	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	common	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	associated with	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	ecg nos	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	change	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	suggestive of	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	myocardial ischaemia	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	myocardial ischemia	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	increased	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	risk	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	death	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
182	death, nos	Elevated troponin level after acute stroke is common and is associated with ECG changes suggestive of myocardial ischemia and increased risk of death.	Affirmed
183	administration	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	fluoroquinolones	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	risk factor	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	for	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	quebec	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	epidemic	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	cause	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
183	strain	Administration of fluoroquinolones emerged as the most important risk factor for CDAD in Quebec during an epidemic caused by a hypervirulent strain of C. difficile.	Affirmed
184	estrogen replacement therapy	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	doses	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	used	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	to	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	control	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	climacteric symptom	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	not	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	altered	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	incidence	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	intensity	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	nocturnal	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	periodic	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
184	limb movement	Estrogen replacement therapy in doses used to control climacteric symptoms does not alter the incidence or intensity of nocturnal periodic limb movements.	Affirmed
185	evidence	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	insufficient	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	show	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	exercise	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	effective treatment	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	menopausal	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	symptoms vasomotor	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	vasomotor	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
185	menopausal symptoms	Evidence was insufficient to show whether exercise is an effective treatment for vasomotor menopausal symptoms.	Affirmed
186	evidence	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	insufficient	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	show	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	relative	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	effectiveness	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	exercise	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	compared	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	ht	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
186	yoga	Evidence was insufficient to show the relative effectiveness of exercise when compared with HT or yoga.	Affirmed
187	temporal distribution	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	plm	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	coupling	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	with	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	phase	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	position	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	temperature	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	curve	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	suggest	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	involvement	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	circadian timing system	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	in	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
187	pathophysiology	The temporal distribution of PLMs, as well as the coupling of PLMs with the phase position of circadian temperature curve, suggest an involvement of the circadian timing system in the pathophysiology of PLMD.	Affirmed
188	locomotor activity	Locomotor activity in animals clearly exhibits a circadian pattern and can be strongly influenced by exogenous melatonin.	Affirmed
188	animals	Locomotor activity in animals clearly exhibits a circadian pattern and can be strongly influenced by exogenous melatonin.	Affirmed
188	exhibit	Locomotor activity in animals clearly exhibits a circadian pattern and can be strongly influenced by exogenous melatonin.	Affirmed
188	pattern	Locomotor activity in animals clearly exhibits a circadian pattern and can be strongly influenced by exogenous melatonin.	Affirmed
188	exogenous	Locomotor activity in animals clearly exhibits a circadian pattern and can be strongly influenced by exogenous melatonin.	Affirmed
188	melatonin	Locomotor activity in animals clearly exhibits a circadian pattern and can be strongly influenced by exogenous melatonin.	Affirmed
189	more	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	mode of action	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	melatonin	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	presented	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	patients	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	increase	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	output	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	amplitude	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	circadian timing system	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	enhance	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	circadian locomotor activity rhythm	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	with	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	sleep reduction	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
189	motor activity	More specifically, we hypothesize that the mode of action of melatonin in the presented PLMD patients might have been an increase of output-amplitude of the circadian timing system, thereby enhancing the circadian rhythmicity of locomotor activity with a reduction of sleep motor activity.	Affirmed
191	subject	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	more	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	severe asthma	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	age	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	associated with	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	reduced	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	expiratory	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	flow	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	female	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	parents	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	asthma	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	increased	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	risk	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
191	adult	The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult.	Affirmed
192	findings	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	treatment	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	prognosis	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	childhood asthma	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	targeting	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	preventive	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	education strategies	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	understanding	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	onset	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	asthma	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	adult	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
192	life	These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies and understanding the onset of asthma in adult life.	Affirmed
193	findings	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	support	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	use of	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	prescribed	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	exercise, aerobic	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	patient management	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	fatigue	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	lupus erythematosus, systemic	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
193	systemic lupus erythematosus	These findings support the use of appropriately prescribed graded aerobic exercise in the management of patients with fatigue and systemic lupus erythematosus.	Affirmed
194	febuxostat	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	at	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	daily dose	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	more	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	effective	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	allopurinol	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	used	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	fixed	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	lowering	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
194	serum urate	Febuxostat, at a daily dose of 80 mg or 120 mg, was more effective than allopurinol at the commonly used fixed daily dose of 300 mg in lowering serum urate.	Affirmed
195	gtn	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	appear	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	to	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	short-term	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	benefits	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	months	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	in	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	treatment	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	lateral	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	>5	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	years	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	not	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	significant	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	clinical	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	compared	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	patients	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	undertaking	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	standard	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	tendon	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	rehabilitation	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	program	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
195	alone	While GTN appears to offer short-term benefits up to 6 months in the treatment of lateral epicondylosis, at 5 years there does not appear to be significant clinical benefits when compared with patients undertaking a standard tendon rehabilitation programme alone.	Affirmed
196	contrast	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	findings	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	continued	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	benefits	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	long-term follow-up	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	described	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	literature	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	for	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	patients	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	achilles	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	tendinopathy	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	treated with	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
196	gtn	This is in contrast to findings of continued benefits at long-term follow-up described in the literature for patients with Achilles tendinopathy treated with GTN.	Affirmed
197	limited	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	available	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	evidence	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	suggest	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	folate	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	potential	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	role	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	supplement	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	to	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	treatment	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	depression	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
197	depression nos	The limited available evidence suggests folate may have a potential role as a supplement to other treatment for depression.	Affirmed
198	currently	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	case	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	both	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	people	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	normal folate	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	levels	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	and	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
198	folate deficiency	It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency.	Affirmed
199	long-term	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	mortality	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	follow-up	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	show	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	patients	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	dyslipidaemia	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	benefit	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	beginning	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	treatment	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	gemfibrosil	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	early	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	factor	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	related	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
199	metabolic syndrome	Long-term mortality follow-up showed that patients with dyslipidemia benefited from beginning treatment with gemfibrozil early, especially if their dyslipidemia entailed factors related to the metabolic syndrome.	Affirmed
200	histologic	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	findings	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	severe	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	gastric atrophy	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	corpus	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	gastritis	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	intestinal metaplasia	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	are	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	increased	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
200	risk	Those with histologic findings of severe gastric atrophy, corpus-predominant gastritis, or intestinal metaplasia are at increased risk.	Affirmed
201	persons	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	h pylori infection	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	non ulcer dyspepsia	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	ulcers, gastric	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	gastric hyperplastic polyps	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	risk	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	ulcers, duodenal	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
201	not	Persons with H. pylori infection and nonulcer dyspepsia, gastric ulcers, or gastric hyperplastic polyps are also at risk, but those with duodenal ulcers are not.	Affirmed
202	insufficient	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	evidence	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	support	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	use of	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	herbal medicines	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	hiv	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	infected	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	individual	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
202	aids patients	There is insufficient evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients.	Affirmed
203	women	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	wish	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	to	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	use	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	combined	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	oc	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	decision	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	unlikely	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	place	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
203	high-risk cancer	Women wishing to use combined OC can be reassured that their decision is unlikely to place them at higher risk of developing cancer.	Affirmed
204	use of	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	vaccine	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	reduced	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	rate	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	anal intraepithelial neoplasia	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	including	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	grade 2	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	<3	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	men	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
204	sex	Use of the qHPV vaccine reduced the rates of anal intraepithelial neoplasia, including of grade 2 or 3, among men who have sex with men.	Affirmed
205	increasing	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	levels	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	pharmacologic	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	acid	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	suppression	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	associated with	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	risks	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	hospital acquired infection	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	increased	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
205	nosocomial infection	Increasing levels of pharmacologic acid suppression are associated with increased risks of nosocomial C difficile infection.	Affirmed
206	this	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	evidence of	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	dose	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	response	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	effect	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	provides	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	provide	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	further	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	support	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	causality	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	nature	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	iatrogenic	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	acid	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	suppression	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	causalities	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	in	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	development	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
206	nosocomial infection	This evidence of a dose-response effect provides further support for the potentially causal nature of iatrogenic acid suppression in the development of nosocomial C difficile infection.	Affirmed
207	infected	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	women	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	maximum	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	possible	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	risk	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	congenital abnormality	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	b19	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	long-term	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	development	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
207	normal	Infected women can be reassured that the maximum possible risk of a congenital abnormality due to B19 is under 1% and that long term development will be normal.	Affirmed
208	ankyloglossia	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	play	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	plays	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	significant	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	role	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	early	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	breast feeding difficulties	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	effective	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	therapy	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
208	difficulties	We speculate that ankyloglossia plays a significant role in early breast-feeding difficulties, and that frenotomy is an effective therapy for these difficulties.	Affirmed
209	children	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	follow-up	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	years	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	provided	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	moderate	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	amount	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	protection	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	ear infections	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	reducing	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	frequent otitis media	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	tube	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	procedures	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	greater	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	amounts	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
209	tube nos	In children followed up to 3.5 years, PCV provided a moderate amount of protection against ear infections while reducing frequent otitis media and tube procedures by greater amounts.	Affirmed
210	combination	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	low dose	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	spironolactone	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	low-dose	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	low	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	spironolactone dose	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	metformin	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	superior	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	drug	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	alone	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	term	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	clinical	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	benefits	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	compliance	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	women	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	pco	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
210	pcos	The combination of low-dose spironolactone with metformin seems superior to either drug alone in terms of clinical benefits and compliance in women with PCOS.	Affirmed
212	plasma lipid	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	levels	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	more	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	associated with	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	increased	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	risk	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	inflammatory	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	marker	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	c-reactive protein level	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	significant	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	prediction	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	coronary	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
212	diseases of the heart	Although plasma lipid levels were more strongly associated with an increased risk than were inflammatory markers, the level of C-reactive protein remained a significant contributor to the prediction of coronary heart disease.	Affirmed
213	daily	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	ingestion	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	ounces	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	yoghurt	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	containing	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	lactobacillus acidophilus	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	decreased	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	candidal	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
213	infection, nos	Daily ingestion of 8 ounces of yogurt containing Lactobacillus acidophilus decreased both candidal colonization and infection.	Affirmed
214	heterogeneity	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	study design	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	need	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	to	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	address	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	future	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	research	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	order	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	test	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	efficacy	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
214	intervention	Heterogeneity in study design needs to be addressed in future research in order to test the efficacy of this intervention.	Affirmed
215	international	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	cough	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	guidelines	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	recommend	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	trial	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	ics	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	only	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	considered	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	patients	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	evaluation	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	including	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	chest x-ray	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	consideration	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	spirometry	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	appropriate	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
215	investigations	International cough guidelines recommend that a trial of ICS should only be considered in patients after thorough evaluation including chest X-ray and consideration of spirometry and other appropriate investigations.	Affirmed
216	episodic	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	high dose	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	inhaled	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	corticosteroids	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	provide	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	effective treatment	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	strategy	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	mild	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	viral	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	wheeze	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
216	childhood	Episodic high dose inhaled corticosteroids provide a partially effective strategy for the treatment of mild episodic viral wheeze of childhood.	Affirmed
217	current	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	evidence	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	favor	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	maintenance dose	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	low	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	inhaled	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	corticosteroids	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	prevention	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	maintenance	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	low dose	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	low-dose	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	management	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	episodic	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	mild	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	viral	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	induced	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
217	wheeze	There is no current evidence to favour maintenance low dose inhaled corticosteroids in the prevention and management of episodic mild viral induced wheeze.	Affirmed
218	patients	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	recently	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	acute coronary syndrome	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	lipid	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	lowering	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	statin	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	regimen	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	provides	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	provide	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	greater	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	protection	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	death	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	death, nos	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	major	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	cardiovascular events	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
218	standard	Among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.	Affirmed
219	findings	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	patients	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	benefit	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	early	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	continued	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	lowering	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	cholesterol, ldl	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	ldl cholesterol	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	to	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	levels	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	current	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
219	target	These findings indicate that such patients benefit from early and continued lowering of LDL cholesterol to levels substantially below current target levels.	Affirmed
252	result	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	only	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	a small	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	proportion	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	children	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	severe	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	alopecia areata	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	obtain	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	persistent	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	benefit	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	topical	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
252	immunotherapy	Our results indicate that only a small proportion of children with severe alopecia areata will obtain a persistent benefit from topical immunotherapy.	Affirmed
253	in	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	patients	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	doppler	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	evidence of	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	diastolic dysfunction	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	rest	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	hypertensive	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	response	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	exercise	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	receptor	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	blockade	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	increase	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	exercise tolerance	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
253	quality of life	In patients with Doppler evidence of diastolic dysfunction at rest and a hypertensive response to exercise, Ang II receptor blockade blunts the hypertensive response to exercise, increases exercise tolerance and improves quality of life.	Affirmed
254	maternal	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	caffeine high	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	intake	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	pregnancy	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	associated with	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	high risk of	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	deliver	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
254	low-birth-weight infants	Higher maternal caffeine intake during pregnancy was associated with a higher risk of delivering low birth weight infants.	Affirmed
255	insufficient	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	evidence	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	support	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	effectiveness	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	melatonin	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	managing	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	cognitive	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	non	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	sequelae	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
255	dementia	There is insufficient evidence to support the effectiveness of melatonin in managing the cognitive and non-cognitive sequelae of dementia.	Affirmed
256	review, systematic	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	meta-analysis	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	performed	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	randomized	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	controlled	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	direct	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	comparison	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	trial	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	included	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	adults	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	receive	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	atenolol	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	bisoprolol	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	metoprolol	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	nebivolol	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	carvedilol	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	evaluate	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	effects	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	compared	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	mortality	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	cardiovascular events	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	hospital readmissions	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	setting	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	systolic	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
256	hf	A systematic review and meta-analysis was performed of randomized, controlled, direct-comparison trials that included adults receiving atenolol, bisoprolol, metoprolol, nebivolol, or carvedilol to evaluate the effects of carvedilol compared to other BBs on mortality, cardiovascular events, and hospital readmissions in the setting of AMI or systolic HF.	Affirmed
257	in	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	trial	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	patients	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	n nos	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	carvedilol	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	reduced	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	all	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	cause	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	mortality	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	fixed	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	effects	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	model	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	risk ratio	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	55	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	confidence interval	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	p nos	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	p'	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	random	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	with	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	reduction	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	non	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	fatal	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
257	31	In 3 trials of patients with AMI (n = 644), carvedilol significantly reduced all-cause mortality by 45% (fixed-effects model: risk ratio 0.55, 95% confidence interval 0.32 to 0.94, p = 0.03, random-effects model: risk ratio 0.56, 95% confidence interval 0.26 to 1.12, p = 0.10), with no reduction in non-fatal MI (risk ratio 0.61, 95% confidence interval 0.31 to 1.22, p = 0.16).	Affirmed
258	conclusion	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	carvedilol	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	compared	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	atenolol	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	bisoprolol	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	metoprolol	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	nebivolol	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	randomized trial	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	direct	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	comparison	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	reduced	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	all	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	cause	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	mortality	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	systolic	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	hf	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
258	patients	In conclusion, carvedilol, as compared against atenolol, bisoprolol, metoprolol and nebivolol in randomized direct comparison trials, significantly reduced all-cause mortality in systolic HF patients.	Affirmed
259	metformin	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	personal treatment	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	at risk	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	diabetes	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	at	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	diabetes risk	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	weight	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	lipid	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	profile	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	insulin resistance	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
259	new onset	Metformin treatment in persons at risk for diabetes improves weight, lipid profiles, and insulin resistance, and reduces new-onset diabetes by 40%.	Affirmed
260	methylprednisolone	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	injections	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	cts	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	significant	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	benefits	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	symptom relieving	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	weeks	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	reducing	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	rate	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	surgery	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	year	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	treatment	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	3 4	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	out	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
260	patients	Methylprednisolone injections for CTS have significant benefits in relieving symptoms at 10 weeks and reducing the rate of surgery 1 year after treatment, but 3 out of 4 patients had surgery within 1 year.	Affirmed
261	primary	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
261	funding source	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
261	region	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
261	research and development	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
261	foundation	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
261	hospital organization	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
261	h nos	PRIMARY FUNDING SOURCE: Region of Scania Research and Development Foundation and HÃ¤ssleholm Hospital Organization.	Affirmed
262	migraine	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
262	women of child bearing age	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
262	increase	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
262	risk	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
262	ischaemic	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
262	not	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
262	haemorrhagic stroke	Migraine in women of childbearing age significantly increases the risk of ischaemic but not haemorrhagic stroke.	Affirmed
263	oral contraceptive use	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	blood pressure, high	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	high blood pressure	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	smoking	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	to	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	exert	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	greater than	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	effect	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	on	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	risk	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	ischaemic stroke	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	ischemic stroke	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	ischaemic	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	stroke risk	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	associated with	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
263	migraine	The coexistence of oral contraceptive use, high blood pressure, or smoking seems to exert a greater than multiplicative effect on the risk of ischaemic stroke associated with migraine.	Affirmed
267	not	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	use	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	tool	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	tongue tied	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	infants	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	at risk	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	breast feeding problems	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
267	breastfeeding problems	The ATLFF was not a useful tool to identify which tongue-tied infants are at risk for breast-feeding problems.	Affirmed
268	clonidine	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	ssris	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	snri	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	gabapentin	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	relaxation therapy	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	show	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	mild to moderate	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	effect	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	reducing	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	hot flushes	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	in	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	women	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
268	history of breast cancer	Clonidine, SSRIs and SNRIs, gabapentin and relaxation therapy showed a mild to moderate effect on reducing hot flushes in women with a history of breast cancer.	Affirmed
271	found	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	exposure to	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	nsaids	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	opioids	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	>90	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	days	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	<90	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	period	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	humeral shaft fracture	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
271	associated with	We found that exposure to nonselective NSAIDs or opioids in the period 61-90 days after a humeral shaft fracture was associated with nonunion.	Affirmed
273	limited	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	evidence	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	controlled trial	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	use of	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	oestrogens	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	prevention	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	management	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
273	pelvic organ prolapse	There was limited evidence from randomised controlled trials regarding the use of oestrogens for the prevention and management of pelvic organ prolapse.	Affirmed
274	use of	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	local	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	estrogen	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	conjunction	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	pelvic floor muscle	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	training	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	surgery	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	incidence	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	post-operative	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	cystitis	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	post operative	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	within	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	four	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
274	weeks	The use of local oestrogen in conjunction with pelvic floor muscle training before surgery may reduce the incidence of post-operative cystitis within four weeks after surgery.	Affirmed
277	additional	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	studies	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	needed	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	to	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	efficacy	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	intervention	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	practice	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
277	setting	However, additional studies are needed to demonstrate the efficacy of this intervention in practice settings.	Affirmed
278	care	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	pre-operative evaluation	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	patient selection	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	resection	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	symptomatic	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	interdigital neuroma	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	dorsal approach	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	result	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	high	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	percentage	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	successful	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	five	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	years	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	following	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
278	procedure	With careful preoperative evaluation and patient selection, resection of a symptomatic interdigital neuroma through a dorsal approach can result in a high percentage of successful results more than five years following the procedure.	Affirmed
279	result	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	suggest	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	opioid	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	therapy	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	effect	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	pain	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	pain nos	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	positive	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	mood	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	little nos	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	activity	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	little	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
279	sleep	The results suggest that opioid therapy has a positive effect on pain and mood but little effect on activity and sleep.	Affirmed
280	evidence of	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	short-term	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	efficacy	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	moderate pain	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	small	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	function	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	opioids	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	treat	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	compared	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
280	placebo	There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo.	Affirmed
281	oc	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	users	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	carrying	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	brca1 mutation	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	reduced	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	risk	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	ovarian cancer	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	ovarian	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	cancer risk	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	proportional	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
281	duration of use	OC users carrying an ascertained BRCA1/2 mutation have a reduced risk of ovarian cancer, proportional to the duration of use.	Affirmed
283	early	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	administration of steroid	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	oral	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	medication, nos	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	medication	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	administration of medication	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	steroid	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	in	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	patients	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	acute sciatica	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	no effect	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	significant	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	parameters	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
283	study	Early administration of oral steroid medication in patients with acute sciatica had no significant effect on most parameters studied.	Affirmed
285	impact	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	oral	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	steroids	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	outcome	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	suggest	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	study	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	small size	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	sample	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	small	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	sample size	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	limited	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
285	statistical power	The impact of oral steroids on other outcomes is suggested by this study, but its small sample size limited its statistical power.	Affirmed
286	small size	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	sample	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	small	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	sample size	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	short-term	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	study	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	further	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	long-term study	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	needed	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	to	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
286	efficacy	However, because of the small sample size and the short term of this study, further long-term studies are needed to determine the efficacy of p.o.	Affirmed
287	procedure	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	circumcision	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	associated with	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	pain	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	pain nos	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	discomfort	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	take	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	less	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	time	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	preferred	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	compared	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
287	plastibell	During the procedure, Mogen circumcision is associated with less pain and discomfort, takes less time, and is preferred by trainees when compared with the PlastiBell.	Affirmed
288	methacholine	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	responsive	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	peak flow	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	variability	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	assessed	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	age	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	together	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	marker	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	atopy	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	skin test	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	reactive	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	allergens	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	three	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	different	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	wheezing	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	phenotypes	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	childhood	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	transient	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	early	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	limited	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	first	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	years	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	life	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	unrelated	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	increased	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	airway, nos	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	airway	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	non	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	atopic	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	toddler	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	school	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	associated with	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	positive	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	not	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	associated	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	wheeze	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	asthma	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	persistent	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
288	and	Methacholine responsiveness and peak flow variability assessed at age 11, together with markers of atopy (IgE and skin test reactivity to allergens) identify three different wheezing phenotypes in childhood: "transient early wheezing" limited to the first three years of life and unrelated to increased airway lability; "non-atopic wheezing" of the toddler and early school years associated with positive peak flow variability but not with methacholine hyperresponsiveness; and "IgE-associated wheeze/asthma" associated with persistent wheezing at any age and with methacholine hyperresponsiveness, peak flow variability, and markers of atopy.	Affirmed
289	not	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
289	known	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
289	favorable	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
289	result	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
289	pennsaid	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
289	topical preparation	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
289	nsaid	It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations.	Affirmed
291	two	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	patients	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	reported	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	partial	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	complete	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	compleat	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	relieve	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	motor restlessness	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	receive	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
291	pergolide	Two patients reported a partial and 9 patients a complete relieve of motor restlessness while receiving Pergolide.	Affirmed
294	based	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	significant	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	rate	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	side effects	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	opioids	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	lack	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	superiority	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	nsaids	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	not	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	recommended	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	treatment	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
294	chronic	Based on the significant rate of side effects with opioids and the lack of convincing superiority over NSAIDs, opioids are not recommended as a treatment for chronic LBP.	Affirmed
295	attention	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	subgroups	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	patients	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	likely	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	help	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	guide	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	treatment	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	increase	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	clinical research	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	impact	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
295	future	Attention to subgroups of patients will likely help guide treatment, and will likely help increase the clinical impact of future research.	Affirmed
296	clinical	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	recommendations	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	recommendation	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	nsaids	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	considered	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	treatment	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	chronic	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	strength	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
296	strong	CLINICAL RECOMMENDATIONS: Recommendation 1: NSAIDs should be considered as a treatment of chronic LBP (Strength: Strong).	Affirmed
298	recommendation	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	opioids	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	considered	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	treatment	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	chronic	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	possible	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	strength	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
298	weak	Recommendation 2: Opioids may be considered in the treatment of chronic LBP but should be avoided if possible (Strength: Weak).	Affirmed
299	evidence	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	favorable	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	effectiveness	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	compared	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	placebo	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	similar	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	nsaids	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	and	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	significant	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	side effects	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	including	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	decreasing	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	related	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	habituation	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	used	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
299	long-term	There is evidence demonstrating favorable effectiveness compared to placebo, similar effectiveness compared to NSAIDs, and with significant side effects including decreasing effectiveness related to habituation when used long-term.	Affirmed
302	based	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	hypothesis	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	chronic	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	symptom, nos	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	heterogeneous	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	group a	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	disorders	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	categorization	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	certainty	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	specific	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	subgroups	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	certainties	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	guide help	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	future	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	treatment	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
302	decision making	Based on the hypothesis that chronic LBP is a symptom reflective of a heterogeneous group of disorders, categorization of certain patient specific subgroups may be helpful in guiding future treatment decision making.	Affirmed
303	likely	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	inclusion	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	subgroup	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	factor	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	future	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	provide	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	information	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	needed	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	to	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	strength	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	specificity	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	clinical	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
303	recommendations	It is likely that inclusion of subgroup factors in future RCTs will provide information needed to improve the strength and specificity of future clinical recommendations.	Affirmed
304	unfavorable	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	score	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	high	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	rate	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	complications	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	more	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	failed trial of labor	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	help	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	counseling patients	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	considering	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
304	trial of labor	An unfavorable score predicting a high rate of complications and more failed trials of labor may help in counseling patients considering trial of labor.	Affirmed
305	msm	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	age-years	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	old	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	and	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	history	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	anal condyloma	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	history, nos	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	risk	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
305	development	Among MSM 26 years of age and older with and without history of anal condyloma, qHPV reduces the risk of anal condyloma development.	Affirmed
306	associated with	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
306	increased	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
306	stroke risk	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
306	women	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
306	medical	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
306	condition	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
306	stroke	PMVA was associated with an increased risk of stroke, particularly among women without other medical conditions associated with stroke.	Affirmed
307	behavioral	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	risk factors	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	smoking	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	oral contraceptive use	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	markedly	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	increased	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	risk	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	recent	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
307	onset	Behavioral risk factors, specifically smoking and oral contraceptive use, markedly increased the risk of PMVA, as did recent onset of PMVA.	Affirmed
309	evidence of	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	routine	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	prescription	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	ace inhibitor	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	in	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	patients	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	diastolic	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	hf	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
309	inconsistent	Evidence for routine prescription of an ACE inhibitor in patients with diastolic HF (DHF) is inconsistent.	Affirmed
310	present	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	prospective study	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	included	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	normal patients	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	slightly	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	impaired	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	ejection fraction	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	survive	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	first	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	hospitalization	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
310	hf	The present prospective study included patients with normal or slightly impaired ejection fraction (> or =50%) surviving a first hospitalization for HF.	Affirmed
311	assessed	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	long-term	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	prognosis	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	patients	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	according	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	prescription	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	ace inhibitor	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
311	discharge	We assessed the long-term prognosis of these patients according to prescription of an ACE inhibitor at discharge.	Affirmed
312	ace inhibitor therapy	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	prescribed	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	discharge	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	n nos	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	included	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	patients	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	associated with	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	relative	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	decrease	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	in	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	risk	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	year	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	mortality	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	hazard ratio	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	confidence interval	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	p nos	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
312	p'	ACE inhibitor therapy prescribed at discharge in 46% (n = 165) of the 358 included patients was associated with a 30% relative decrease in the risk of 5-year mortality (hazard ratio 0.70, 95% confidence interval 0.53 to 0.93, p = 0.013).	Affirmed
313	analysis	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	relation	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	ace inhibitor	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	prescription	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	mortality	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	significant	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	hazard ratio	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	confidence interval	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	p nos	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
313	p'	On multivariable Cox analysis, the relation between ACE inhibitor prescription and mortality remained significant (hazard ratio 0.73, 95% confidence interval 0.54 to 0.99, p = 0.045).	Affirmed
314	using	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	propensity score	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	analysis	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	patients	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	receive	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	ace inhibitor	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	matched	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	not	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	medication, nos	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
314	medication	Using propensity score analysis, 120 patients receiving an ACE inhibitor were matched with 120 patients not receiving this medication.	Affirmed
315	group	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	prescription	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	ace inhibitor	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	associated with	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	significant	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	decrease	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	in	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	risk	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	year	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	mortality	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	hazard ratio	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	confidence interval	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	p nos	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
315	p'	In the postmatch group, prescription of ACE inhibitor was associated with a significant decrease in the risk of 5-year mortality (hazard ratio 0.61, 95% confidence interval 0.43 to 0.87, p = 0.006).	Affirmed
316	five	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	year	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	relative survival	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	observed	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	expected	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	survival	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	ace inhibitor	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	group	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	better	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
316	65	Five-year relative survival (observed/expected survival) of the ACE inhibitor group was better than that of the no-ACE inhibitor group (65% vs 57%).	Affirmed
317	conclusion	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	cohort	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	patients	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	prescription	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	ace inhibitor	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	associated with	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	significant	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	decrease	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	long-term	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
317	mortality	In conclusion, we demonstrate that in this cohort of patients with DHF, prescription of ACE inhibitor was associated with a significant decrease in long-term mortality.	Affirmed
318	elevated	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	troponin	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	levels	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	patients	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	acute pulmonary embolism nos	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	at	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	high risk of	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	short-term	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	death	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	death, nos	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	adverse events	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
318	outcome	Elevated troponin levels identify patients with acute pulmonary embolism at high risk of short-term death and adverse outcome events.	Affirmed
320	early	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	surgery	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	more	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	rapid	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	relief	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	sciatica	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	care	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	outcome	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	similar	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	one	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	year	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	not	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	change	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
320	second	Early surgery achieved more rapid relief of sciatica than conservative care, but outcomes were similar by one year and these did not change during the second year.	Affirmed
321	risk	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	maternal infection	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	b19	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	maternal	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	infection risk	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	pregnancy	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	not	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	predicted	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	gravida	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	occupation	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	high	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	source	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	exposure, nos	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	exposure	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
321	child	The risk of maternal B19 infection in pregnancy could not be predicted by a gravida's occupation, but it was significantly higher when the source of exposure was her own child.	Affirmed
323	short-term	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	effects	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	of	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	maternal	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	medications	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	breast fed	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	infants	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	mild	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	little nos	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	risk	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
323	little	The short-term effects, if any, of most maternal medications on breast-fed infants are mild and pose little risk to the infants.	Affirmed
324	found	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	expense	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	therapy	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	effective	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	complete	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	cure-for-all	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	toenails	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
324	compleat	We also found this expensive therapy to be much less effective than previously believed, particularly for achieving complete cure of all 10 toenails.	Affirmed
326	early	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	not	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	result	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	objective improvement	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	breast feeding	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	associated with	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	improved	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
326	self efficacy	Early frenotomy did not result in an objective improvement in breastfeeding but was associated with improved self-efficacy.	Affirmed
327	randomized controlled trial	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	show	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	'tongue-tie'	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	affect	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	feeding	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	division	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	successful	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	improved	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	mother	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	baby	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	better	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	skilled	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	lactation support	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	consultant	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	support	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
327	lactation consultant	This randomized, controlled trial has clearly shown that tongue-ties can affect feeding and that division is safe, successful and improved feeding for mother and baby significantly better than the intensive skilled support of a lactation consultant.	Affirmed
328	red yeast rice	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	therapeutic	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	life style change	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	decrease	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	ldl cholesterol level	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	increasing	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	pain level	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	treatment option	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	dyslipidaemia	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	patients	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	statin	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
328	therapy	Red yeast rice and therapeutic lifestyle change decrease LDL cholesterol level without increasing CPK or pain levels and may be a treatment option for dyslipidemic patients who cannot tolerate statin therapy.	Affirmed
329	gps	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	counseling	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	physical activity	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	counselling	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	counseling nos	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	using	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	pace protocol	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	mediators	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	biometry	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	outcome	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	italian	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	primary care	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
329	context	The GPs' counseling for physical activity using the PACE protocol influenced mediators and biometrical outcomes in an Italian primary care context.	Affirmed
330	reduction	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	posterior pain	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	pelvic	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	posterior	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	pelvic pain	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	pelvic pain, nos	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	non	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	elastic	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	pelvic support	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	experience	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
330	women	Reduction of posterior pelvic pain by a non-elastic pelvic support was experienced by 82% of the women with posterior pelvic pain.	Affirmed
331	heptavalent pneumococcal conjugate vaccine	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	introduction	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	children	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	less	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	likely	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	frequent otitis media	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	pressure	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
331	tube insertions	After heptavalent pneumococcal conjugate vaccine introduction, children were less likely to develop frequent otitis media or have pressure-equalizing tube insertions.	Affirmed
332	rate	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
332	spontaneous	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
332	passage	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
332	ureteral stone	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
332	stone size	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
332	location	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
332	ct	The rate of spontaneous passage of ureteral stones does vary with stone size and location as determined by CT.	Affirmed
333	evidence	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	insufficient	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	show	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	effectiveness	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	relaxation techniques	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	treatment	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	menopausal symptoms	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	vasomotor	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	menopausal	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	symptoms vasomotor	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	to	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	more	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	effective treatment	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	placebo	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	acupuncture	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	superficial	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	needle	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	insertion	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	pace	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
333	respiration	Evidence is insufficient to show the effectiveness of relaxation techniques as treatment for menopausal vasomotor symptoms, or to determine whether this treatment is more effective than no treatment, placebo, acupuncture, superficial needle insertion or paced respiration.	Affirmed
334	in	Furthermore, in the majority of these patients, the elevated blood pressures can be controlled or significantly improved.	Affirmed
334	majority	Furthermore, in the majority of these patients, the elevated blood pressures can be controlled or significantly improved.	Affirmed
334	patients	Furthermore, in the majority of these patients, the elevated blood pressures can be controlled or significantly improved.	Affirmed
334	elevated blood pressure	Furthermore, in the majority of these patients, the elevated blood pressures can be controlled or significantly improved.	Affirmed
334	controlled	Furthermore, in the majority of these patients, the elevated blood pressures can be controlled or significantly improved.	Affirmed
334	improved	Furthermore, in the majority of these patients, the elevated blood pressures can be controlled or significantly improved.	Affirmed
335	data	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	similar	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	previous	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	study	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	rh	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	rh-	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	suboptimal	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	medication, nos	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	regimen	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	medication	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	common	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	reason	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
335	resistance	These data are strikingly similar to those from our previous study of RH, in which a suboptimal medication regimen was the most common reason for resistance.	Affirmed
337	infants	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	significant	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	'tongue-tie'	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	interfering	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	breast feeding	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	show	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	improvement	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
337	following	Infants with a significant tongue-tie that is interfering with breast-feeding have shown an improvement with breast-feeding following frenotomy.	Affirmed
338	infection risk	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	high	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	susceptible	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	pregnant women	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	epidemics	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	associated with	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	level	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	contact	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	associated	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	contact with	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
338	children	The risk of infection is high for susceptible pregnant women during epidemics and associated with the level of contact with children.	Affirmed
339	nursery school	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	teachers	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	nursery	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	school teachers	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	high risk	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	occupational	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	infections	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	to	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	result	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	exposure, nos	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	exposure	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
339	woman child	Nursery school teachers have the highest occupational risk, but most infections seem to be the result of exposure to the woman's own children.	Affirmed
340	h pylori infection	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	nsaid	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	use	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	advanced age	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	independent	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	risk factors	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	subsequent	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	ulcer	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
340	formation	H pylori infection, NSAID use, and advanced age are independent risk factors for subsequent ulcer formation.	Affirmed
341	follow-up	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	endoscopy	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	indicated	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	with	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	multiple	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	risk factors	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	ulcer	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	formation	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	symptoms	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
341	recur	Follow up endoscopy is strongly indicated for an NUD patient with multiple risk factors for ulcer formation when symptoms recur.	Affirmed
342	atypical antipsychotic drugs	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	associated with	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	small	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	increased	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	risk	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	death	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	death, nos	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	compared	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
342	placebo	Atypical antipsychotic drugs may be associated with a small increased risk for death compared with placebo.	Affirmed
343	risk	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	considered	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	context	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	medical	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	need	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	drugs	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	efficacy	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	evidence	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	comorbidity	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	safety	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
343	alternative	This risk should be considered within the context of medical need for the drugs, efficacy evidence, medical comorbidity, and the efficacy and safety of alternatives.	Affirmed
344	compared	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	pravastatin	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	treatment	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	high	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	potential	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	statins	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	atorvastatin	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	simvastatin	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	associated with	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	increased	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	new onset	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
344	diabetes risk	Compared with pravastatin, treatment with higher potency statins, especially atorvastatin and simvastatin, might be associated with an increased risk of new onset diabetes.	Affirmed
345	in	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	pooled	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	data analysis	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	>5	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	statin	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	trial	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	dose	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	therapy	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	associated with	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	increased	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	new onset	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	diabetes risk	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	compared	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
345	moderate-dose	In a pooled analysis of data from 5 statin trials, intensive-dose statin therapy was associated with an increased risk of new-onset diabetes compared with moderate-dose statin therapy.	Affirmed
346	in person	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	trial	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	apparently	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	health	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	healthiness	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	hyperlipidaemia	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	hyperlipidemia	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	but	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	elevated	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	high sensitivity	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	c-reactive protein level	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	rosuvastatin	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	reduced	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	incidence	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	major	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
346	cardiovascular events	In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.	Affirmed
347	efficacy	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	same	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	treating	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	syndromes, depressive	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	disorders	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	superior	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	placebo	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	standard	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	antidepressants, tricyclic	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
347	tricyclic antidepressants	The efficacy of SAMe in treating depressive syndromes and disorders is superior with that of placebo and comparable to that of standard tricyclic antidepressants.	Affirmed
348	same	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
348	occur	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
348	compound	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
348	side effects	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
348	treatment	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
348	depression	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
348	depression nos	Since SAMe is a naturally occurring compound with relatively few side-effects, it is a potentially important treatment for depression.	Affirmed
349	further	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	study	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	same	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	independent	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	adjuvant therapy	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	major depression	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	adults	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
349	indicated	Further study of SAMe as independent and adjuvant therapy for major depression in adults is indicated.	Affirmed
350	curcumin	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
350	to	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
350	six	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
350	human	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
350	trial	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
350	anti-inflammatory	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
350	activity	Curcumin has been demonstrated to be safe in six human trials and has demonstrated anti-inflammatory activity.	Affirmed
351	exert	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	anti a	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	inflammatory	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	activity	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	inhibition	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	different	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	molecules	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	number	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	play	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	role	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
351	inflammation	It may exert its anti-inflammatory activity by inhibition of a number of different molecules that play a role in inflammation.	Affirmed
352	more	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	head	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	clinical trials	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	needed	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	direct	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	comparison	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	frequency	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	these	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	preliminary	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	data reports	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	separate	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	suggest	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	possible	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	aes	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	less	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	likely	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	doxycycline	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
352	minocycline	Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.	Affirmed
353	counseling	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	counselling	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	counseling nos	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	pharmacotherapy	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	promote	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	sustained	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	weightloss	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	weight loss	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	improving	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	clinical	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
353	outcome	Counseling and pharmacotherapy can promote modest sustained weight loss, improving clinical outcomes.	Affirmed
354	pharmacotherapy	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
354	appear	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
354	short-term	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
354	long-term	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
354	safety	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
354	not	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
354	established	Pharmacotherapy appears safe in the short term; long-term safety has not been as strongly established.	Affirmed
355	select	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	patients	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	surgery	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	promote	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	large	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	amounts	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	loss of weight	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	rare	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	sometimes	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	severe	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
355	complications	In selected patients, surgery promotes large amounts of weight loss with rare but sometimes severe complications.	Affirmed
356	evidence of	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	significant	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	reduction	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	in	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	mortality	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	men	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	aged	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	65	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	years	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	ultrasound	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
356	screening	There is evidence of a significant reduction in mortality from AAA in men aged 65 to 79 years who undergo ultrasound screening.	Affirmed
357	findings	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	need	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	care	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	consideration	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	judge	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	program, population	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	based	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	screening	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
357	introduce	These findings need careful consideration in judging whether a co-ordinated population-based screening programme should be introduced.	Affirmed
358	several	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	aspect	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	screening	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	study	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	to	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	optimal	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	methods	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	including	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	instrument	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	use	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	age	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	screen	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	interval	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
358	most	Several aspects of screening have been inadequately studied to determine optimal methods, including which instrument to use, the age at which to screen, and which interval is most useful.	Affirmed
359	intervention trials	Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited.	Affirmed
359	improvement	Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited.	Affirmed
359	outcome measures	Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited.	Affirmed
359	conclusions	Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited.	Affirmed
359	limited	Trials of interventions demonstrate improvement in some outcome measures, but conclusions and generalizability are limited.	Affirmed
360	data	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	not available	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	address	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	issue	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	including	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	effectiveness	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	screening	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	primary care	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	setting	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	role enhancement	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	surveillance	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	referral by physician	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	diagnostic evaluation	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	non	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	speech	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	language	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	long-term	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	benefits	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	interventions	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
360	adverse effects	Data are not available addressing other key issues including the effectiveness of screening in primary care settings, role of enhanced surveillance by primary care physicians before referral for diagnostic evaluation, non-speech and language and long-term benefits of interventions, and adverse effects of screening and interventions.	Affirmed
361	use of	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	sensitive	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	assay	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	troponin i	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	early diagnosis	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	acute myocardial infarction	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	risk	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	stratification	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	regardless	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	time of onset	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
361	chest pain	The use of a sensitive assay for troponin I improves early diagnosis of acute myocardial infarction and risk stratification, regardless of the time of chest-pain onset.	Affirmed
364	results study	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	show	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	one	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	application	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	silver nitrate	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	decrease	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	pain severity	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	in	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	aphthous ulceration	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	shortening	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	healing	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
364	time	The results of our study showed that one application of silver nitrate can decrease the severity of pain in aphthous ulceration without significantly shortening or prolonging healing time.	Affirmed
365	study	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	design	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	to	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	evaluate	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	anti-oxidant effects	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	flavonoid	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	silymarin	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	improving	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	long-term	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	postprandial	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	glycemia	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	weight control	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	type 2	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	diabetic	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	patients	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	treated with	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
365	glibenclamide	This study was designed to evaluate the effects of the antioxidant flavonoid silymarin in improving long-term and postprandial glycemic and weight control in type 2 diabetic patients treated with glibenclamide.	Affirmed
366	using	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	randomized	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	double blind	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	placebo-controlled	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	design	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	type 2	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	diabetic	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	patients	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	maintained	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	mg day	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	glibenclamide	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	dietary control	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	poor glycaemic control	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	three	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	group	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	groups	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	first	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	two	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	treated with	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	silymarin	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	placebo	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	third	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	alone	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
366	days	Using a randomized, double-blind, placebo-controlled design, 59 type 2 diabetic patients, previously maintained on 10 mg/day glibenclamide and diet control, with poor glycemic control, were randomized into three groups: the first two groups were treated with either 200 mg/day silymarin or placebo as adjuncts to glibenclamide, and the third group was maintained on glibenclamide alone for 120 days.	Affirmed
367	fasting	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	4 hour	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	postprandial	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	plasma glucose	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	glycated haemoglobin	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	hba	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	body mass index	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	evaluated	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	baseline	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	and	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
367	days	Fasting and 4-hour postprandial plasma glucose, glycated hemoglobin (HbA(1c)), and body mass index (BMI) were evaluated at baseline and after 120 days.	Affirmed
369	conclusion	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	use of	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	silymarin	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	glibenclamide	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	glycemia	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	control	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	targeted	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	fasting	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	effect	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	related	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	increased insulin	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	sensitive to	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	peripheral	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
369	tissues	In conclusion, adjunct use of silymarin with glibenclamide improves the glycemic control targeted by glibenclamide, during both fasting and postprandially, an effect that may be related to increased insulin sensitivity in peripheral tissues.	Affirmed
370	prediction	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	success	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	at	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	time	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	admission	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	highly	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	dependent	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	initial	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
370	cervical	Prediction of TOLAC success at the time of admission is highly dependent on the initial cervical examination.	Affirmed
371	single	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	dose reduced	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	famciclovir	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	time	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	healing	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	herpes labialis	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	lesion	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	approximately	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	days	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	compared	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
371	placebo	Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.	Affirmed
372	simple	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	smoking cessation advice	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	combined	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	spirometry testing	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	result	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	good	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	year	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	cessation	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	rate	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	subject	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
372	airway obstruction	Simple smoking cessation advice combined with spirometric testing resulted in good 1 year cessation rates, especially in subjects with airway obstruction.	Affirmed
373	half	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	patients	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	presented	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	disease control	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	after-treatment	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	last	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	average	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	approximately	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	one	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
373	year	Half of the patients presented disease control after treatment lasting an average of approximately one year.	Affirmed
374	low dose	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	sodium valproate	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	low-dose	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	effective	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	reducing	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	broad	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	range	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	types	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	behaviours	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	aggressive	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	demented	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
374	patients	Low dose sodium valproate may be effective reducing a broad range of types of disturbed behaviours in aggressive demented patients.	Affirmed
377	review	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	show	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	overall	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	effect	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	speech and language therapy	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	interventions	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	positive	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	for children	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	phonologies	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	vocabulary	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
377	difficulties	The review shows that overall there is a positive effect of speech and language therapy interventions for children with expressive phonological and expressive vocabulary difficulties.	Affirmed
378	evidence	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	syntax difficulties	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	more	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	mixed	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	need	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	further	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	research	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	to	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	investigate	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	intervention	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
378	difficulties language	The evidence for expressive syntax difficulties is more mixed, and there is a need for further research to investigate intervention for receptive language difficulties.	Affirmed
379	large	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
379	degree	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
379	heterogeneity	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
379	result	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
379	sources	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
379	need	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
379	investigated	There is a large degree of heterogeneity in the results, and the sources of this need to be investigated.	Affirmed
380	found	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	no	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	arguments	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	favor	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	smokers	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	with	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	lung function	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	tool	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	enhance	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
380	smoking cessation	We found no arguments in favour of confronting smokers with their lung function as a tool for enhancing smoking cessation.	Affirmed
381	effects	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	multiple	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	treatment options	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	subjective	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	objective	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	measures	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	hirsutism	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	displayed	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
381	result	The effects of multiple treatment options on the subjective and objective measures of hirsutism have displayed varying results.	Affirmed
382	outcome	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	reported date	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	show	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	trend	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	positive	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	using	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	spironolactone	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	women	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	pco	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	pcos	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
382	hirsutism	The outcomes reported to date have shown a positive trend toward using spironolactone in women with PCOS and hirsutism.	Affirmed
384	need	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	further	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	research	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	to	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	performed	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	large	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	sizes, sample	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	well	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	design	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	assess	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	clinical	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
384	outcome	There is a need for further research to be performed with large sample sizes and well-designed RCTs to assess clinical outcomes.	Affirmed
385	studies	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	needed	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	to	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	clarify	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	stroke risk	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	users	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	susceptible	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	basis	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	age	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	smoking	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	obesity	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	hypertension	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	migraine	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	history	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
385	history, nos	Studies are needed to clarify the risk of stroke among users who may be susceptible on the basis of age, smoking, obesity, hypertension, or migraine history.	Affirmed
386	year	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	outcome	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	similar	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	patients	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	assigned	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	early	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	surgery	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	treatment	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	needed	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	rate	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	pain relief	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	and	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	perceived	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	recovery	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
386	fast	The 1-year outcomes were similar for patients assigned to early surgery and those assigned to conservative treatment with eventual surgery if needed, but the rates of pain relief and of perceived recovery were faster for those assigned to early surgery.	Affirmed
387	cancer survivor	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	opioids	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	experience	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	symptomatic	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	hypogonadism	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	high	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	level of depression	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	fatigue	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
387	sexual dysfunction	Survivors of cancer who chronically consumed opioids experienced symptomatic hypogonadism with significantly higher levels of depression, fatigue, and sexual dysfunction.	Affirmed
388	with	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	increasing	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	use of	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	opioids	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	cancer patient	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	further	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	improving	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	quality of life	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
388	outcomes research	With the increasing use of opioids among patients with cancer, further research in improving quality-of-life outcomes is warranted.	Affirmed
390	balance	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	training	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	used	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	acute	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	ankle sprain	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	effort	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	future	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	ankle sprains	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	current	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	evidence	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	insufficient	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	assess	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	this	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	effect	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	patients	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	chronic	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
390	ankle instability	Balance training can be used prophylactically or after an acute ankle sprain in an effort to reduce future ankle sprains, but current evidence is insufficient to assess this effect in patients with chronic ankle instability.	Affirmed
391	further	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	prospective studies	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	patients	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	take	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	long-term	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	acid	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	suppression	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	needed	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	to	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	establish	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	association	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	causality	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
391	causalities	Further prospective studies on patients taking long-term acid suppression are needed to establish whether this association is causal.	Affirmed
392	administration of injection	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	three	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	local	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	cortivazol	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	followed by	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	suppression	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	axis	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	days	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	injection, epidural	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	epidural injection	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	recovered	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	more	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	rapidly	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
392	injection, intraarticular	The administration of three local cortivazol injections was followed by suppression of the corticotropic axis that persisted beyond 21 days after epidural injection and recovered more rapidly after intra-articular injection.	Affirmed
393	excellent	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	cure	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	rate	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	good	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	tolerability	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	profile	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	terbinafine	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	continue	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	to	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	drug	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	choice	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	for	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	treatment	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	onychomycosis toenail	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	in	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	number of patients	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	niddm	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	receive	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	multiple	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	medication, nos	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
393	medication	With excellent cure rates and a good tolerability profile, terbinafine should continue to be a drug of choice for the treatment of toenail onychomycosis in the rising number of NIDDM patients receiving multiple medication.	Affirmed
394	currently	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	available	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	evidence	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	support	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	inference	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	testosterone	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	use	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	men	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	not	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	associated with	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	cardiovascular	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
394	effects	Currently available evidence weakly supports the inference that testosterone use in men is not associated with important cardiovascular effects.	Affirmed
395	patients	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	clinicians	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	need	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	large	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	randomized trial	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	men	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	at	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	cardiovascular disease risk	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	better	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	inform	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	safety	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	long-term	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	testosterone	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
395	use of	Patients and clinicians need large randomized trials of men at risk for cardiovascular disease to better inform the safety of long-term testosterone use.	Affirmed
396	are	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	no	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	large	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	scale	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	long-term study	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	controlled	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	therapy	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	provide	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	definitive	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	risk assessment	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	numerous	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	smaller	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	clinical trials	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	population based study	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	longitudinal	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	fail	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	to	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	support	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	historical	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	ideal	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	t'	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	increased	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	risk	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	cancer of prostate	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	symptoms	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
396	benign prostatic hyperplasia	Although there are as yet no large-scale, long-term controlled studies of T therapy to provide a definitive assessment of risk, numerous smaller clinical trials as well as population-based longitudinal studies consistently fail to support the historical idea that T therapy poses an increased risk of prostate cancer or exacerbation of symptoms due to benign prostatic hyperplasia.	Affirmed
398	contrast	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	mount	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	evidence	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	low	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	serum	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	associated with	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	greater	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	prostate cancer risk	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	more	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	feature	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
398	cancer of prostate	In contrast, there is mounting evidence that low serum T is associated with greater prostate cancer risk, and more worrisome features of prostate cancer.	Affirmed
424	in	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	patients	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	migraine	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	common	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	reasons	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	misdiagnosis	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	include	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	head ache	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	triggers	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	pain	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	location	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	pain nos	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	associated	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	feature	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	guilt	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	provocation	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	association	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	attribute	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
424	sinus headache	In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache.	Affirmed
428	decrease	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	some	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	measurable	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	element, physiologic	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	pain response	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	neonate	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	neonate, nos	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
428	circumcision	NNS significantly decreases some elements of measurable physiologic pain response of the neonate during circumcision.	Affirmed
429	present	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	trial	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	evaluated	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	tolerability	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	red yeast rice	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	pravastatin	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	patients	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	unable	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	other	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	statins	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
429	myalgia	The present trial evaluated the tolerability of red yeast rice versus pravastatin in patients unable to tolerate other statins because of myalgia.	Affirmed
